1
|
Cordier F, Schouten JW, Geurts M, Kros JM, Dubbink HJ, Verlinden V, Federico A, Kool M, Maas SLN. Diffuse infiltrating tumour with the molecular profile of an atypical teratoid rhabdoid tumour (AT/RT SHH-1B) in an adult patient. Neuropathol Appl Neurobiol 2024; 50:e12983. [PMID: 38708554 DOI: 10.1111/nan.12983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2023] [Revised: 04/23/2024] [Accepted: 04/26/2024] [Indexed: 05/07/2024]
Abstract
We describe a 46-year-old patient with an IDH-wildtype diffusely infiltrating atypical teratoid/rhabdoid tumour (AT/RT), SHH-1B molecular subtype. The unusual histology and subsequent diagnosis in an adult patient will be discussed.
Collapse
Affiliation(s)
- Fleur Cordier
- Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
- Department of Pathology, University Hospital Ghent, Ghent, Belgium
| | - Joost W Schouten
- Department of Neurosurgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Marjolein Geurts
- Department of Neurology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Johan M Kros
- Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Hendrikus J Dubbink
- Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Vincent Verlinden
- Department of Radiology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Aniello Federico
- Hopp Childrens Cancer Center (KiTZ), Heidelberg, Germany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Marcel Kool
- Hopp Childrens Cancer Center (KiTZ), Heidelberg, Germany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
- University Medical Center Utrecht, Utrecht, The Netherlands
| | - Sybren L N Maas
- Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
| |
Collapse
|
2
|
Romano L, Napolitano L, Crocetto F, Sciorio C, Priadko K, Fonticelli M, Federico A, Romano M, Gravina AG. The potential therapeutic role of Hericium erinaceus extract in pathologic conditions involving the urogenital-gut axis: insights into the involved mechanisms and mediators. J Physiol Pharmacol 2024; 75. [PMID: 38583434 DOI: 10.26402/jpp.2024.1.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Accepted: 02/29/2024] [Indexed: 04/09/2024]
Abstract
In this review we focused on the putative therapeutic effect of Hericium erinaceus extract in the treatment of pathologic conditions of the lower urinary tract in which intestinal inflammation may play a role. To this aim we reviewed the available evidence on pelvic cross-organ sensitization as a possible mechanism through which intestinal inflammation and dysbiosis may affect the lower urinary tract. Also, we reviewed the clinical and experimental evidence supporting the role of Hericium erinaceus extract as an anti-inflammatory agent highlighting the role of a number of putative mediators and mechanisms which might make this nutraceutical suitable for the management of 'difficult to treat' lower urinary tract disorders.
Collapse
Affiliation(s)
- L Romano
- Department of Neurosciences, Sciences of Reproduction, and Odontostomatology, University of Naples 'Federico II', Naples, Italy
- Unit of Urology, Department of Woman, Child and General and Specialized Surgery, University of Campania 'Luigi Vanvitelli', Naples, Italy
| | - L Napolitano
- Unit of Urology, Department of Woman, Child and General and Specialized Surgery, University of Campania 'Luigi Vanvitelli', Naples, Italy
| | - F Crocetto
- Unit of Urology, Department of Woman, Child and General and Specialized Surgery, University of Campania 'Luigi Vanvitelli', Naples, Italy
| | - C Sciorio
- Division of Urology, A. Manzoni General Hospital, Lecco, Italy
| | - K Priadko
- Department of Precision Medicine and Hepatogastroenterology Unit, University of Campania 'Luigi Vanvitelli', Naples, Italy
| | - M Fonticelli
- Department of Precision Medicine and Hepatogastroenterology Unit, University of Campania 'Luigi Vanvitelli', Naples, Italy
| | - A Federico
- Department of Precision Medicine and Hepatogastroenterology Unit, University of Campania 'Luigi Vanvitelli', Naples, Italy
| | - M Romano
- Department of Precision Medicine and Hepatogastroenterology Unit, University of Campania 'Luigi Vanvitelli', Naples, Italy.
| | - A G Gravina
- Department of Precision Medicine and Hepatogastroenterology Unit, University of Campania 'Luigi Vanvitelli', Naples, Italy
| |
Collapse
|
3
|
Lago C, Federico A, Leva G, Mack NL, Schwalm B, Ballabio C, Gianesello M, Abballe L, Giovannoni I, Reddel S, Rossi S, Leone N, Carai A, Mastronuzzi A, Bisio A, Soldano A, Quintarelli C, Locatelli F, Kool M, Miele E, Tiberi L. Patient- and xenograft-derived organoids recapitulate pediatric brain tumor features and patient treatments. EMBO Mol Med 2023; 15:e18199. [PMID: 38037472 DOI: 10.15252/emmm.202318199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Revised: 10/19/2023] [Accepted: 10/24/2023] [Indexed: 12/02/2023] Open
Abstract
Brain tumors are the leading cause of cancer-related death in children. Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of pediatric brain cancers are limited and hard to establish. We present a protocol that enables efficient generation, expansion, and biobanking of pediatric brain cancer organoids. Utilizing our protocol, we have established patient-derived organoids (PDOs) from ependymomas, medulloblastomas, low-grade glial tumors, and patient-derived xenograft organoids (PDXOs) from medulloblastoma xenografts. PDOs and PDXOs recapitulate histological features, DNA methylation profiles, and intratumor heterogeneity of the tumors from which they were derived. We also showed that PDOs can be xenografted. Most interestingly, when subjected to the same routinely applied therapeutic regimens, PDOs respond similarly to the patients. Taken together, our study highlights the potential of PDOs and PDXOs for research and translational applications for personalized medicine.
Collapse
Affiliation(s)
- Chiara Lago
- Armenise-Harvard Laboratory of Brain Disorders and Cancer, CIBIO, Trento, Italy
| | - Aniello Federico
- Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany
- Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Gloria Leva
- Armenise-Harvard Laboratory of Brain Disorders and Cancer, CIBIO, Trento, Italy
| | - Norman L Mack
- Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany
- Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Benjamin Schwalm
- Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany
- Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Claudio Ballabio
- Armenise-Harvard Laboratory of Brain Disorders and Cancer, CIBIO, Trento, Italy
| | - Matteo Gianesello
- Armenise-Harvard Laboratory of Brain Disorders and Cancer, CIBIO, Trento, Italy
| | - Luana Abballe
- Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Rome, Italy
| | | | - Sofia Reddel
- Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Rome, Italy
| | - Sabrina Rossi
- Pathology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Nicolas Leone
- Pathology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Andrea Carai
- Neurosurgery Unit, Department of Neurosciences, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Angela Mastronuzzi
- Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Rome, Italy
| | - Alessandra Bisio
- Laboratory of Radiobiology, CIBIO, Trento, Italy
- Trento Institute for Fundamental Physics and Application, TIFPA, Trento, Italy
| | - Alessia Soldano
- Department of Neuroscience, Scuola Internazionale Superiore di Studi Avanzati (SISSA), Trieste, Italy
| | - Concetta Quintarelli
- Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Rome, Italy
| | - Franco Locatelli
- Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Rome, Italy
- Catholic University of the Sacred Heart, Rome, Italy
| | - Marcel Kool
- Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany
- Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
- University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
| | - Evelina Miele
- Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Rome, Italy
| | - Luca Tiberi
- Armenise-Harvard Laboratory of Brain Disorders and Cancer, CIBIO, Trento, Italy
| |
Collapse
|
4
|
Del Giudice G, Serra A, Saarimäki LA, Kotsis K, Rouse I, Colibaba SA, Jagiello K, Mikolajczyk A, Fratello M, Papadiamantis AG, Sanabria N, Annala ME, Morikka J, Kinaret PAS, Voyiatzis E, Melagraki G, Afantitis A, Tämm K, Puzyn T, Gulumian M, Lobaskin V, Lynch I, Federico A, Greco D. An ancestral molecular response to nanomaterial particulates. Nat Nanotechnol 2023; 18:957-966. [PMID: 37157020 PMCID: PMC10427433 DOI: 10.1038/s41565-023-01393-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Accepted: 03/31/2023] [Indexed: 05/10/2023]
Abstract
The varied transcriptomic response to nanoparticles has hampered the understanding of the mechanism of action. Here, by performing a meta-analysis of a large collection of transcriptomics data from various engineered nanoparticle exposure studies, we identify common patterns of gene regulation that impact the transcriptomic response. Analysis identifies deregulation of immune functions as a prominent response across different exposure studies. Looking at the promoter regions of these genes, a set of binding sites for zinc finger transcription factors C2H2, involved in cell stress responses, protein misfolding and chromatin remodelling and immunomodulation, is identified. The model can be used to explain the outcomes of mechanism of action and is observed across a range of species indicating this is a conserved part of the innate immune system.
Collapse
Affiliation(s)
- G Del Giudice
- FHAIVE, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
| | - A Serra
- FHAIVE, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Tampere Institute for Advanced Study, Tampere, Finland
| | - L A Saarimäki
- FHAIVE, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
| | - K Kotsis
- School of Physics, University College Dublin, Dublin, Ireland
| | - I Rouse
- School of Physics, University College Dublin, Dublin, Ireland
| | - S A Colibaba
- School of Physics, University College Dublin, Dublin, Ireland
| | - K Jagiello
- Group of Environmental Chemoinformatics, Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland
- QSAR Lab Ltd, Gdańsk, Poland
| | - A Mikolajczyk
- Group of Environmental Chemoinformatics, Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland
- QSAR Lab Ltd, Gdańsk, Poland
| | - M Fratello
- FHAIVE, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
| | - A G Papadiamantis
- School of Geography, Earth and Environmental Sciences, University of Birmingham, Birmingham, UK
- Novamechanics Ltd, Nicosia, Cyprus
| | - N Sanabria
- National Institute for Occupational Health, National Health Laboratory Services, Johannesburg, South Africa
- School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa
| | - M E Annala
- FHAIVE, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
| | - J Morikka
- FHAIVE, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
| | - P A S Kinaret
- FHAIVE, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Institute of Biotechnology, Helsinki Institute of Life Sciences (HiLife), University of Helsinki, Helsinki, Finland
| | | | - G Melagraki
- Division of Physical Sciences and Applications, Hellenic Military Academy, Vari, Greece
| | | | - K Tämm
- Institute of Chemistry, University of Tartu, Tartu, Estonia
| | - T Puzyn
- Group of Environmental Chemoinformatics, Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland
- QSAR Lab Ltd, Gdańsk, Poland
| | - M Gulumian
- National Institute for Occupational Health, National Health Laboratory Services, Johannesburg, South Africa
- Haematology and Molecular Medicine Department, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa
- Water Research Group, Unit for Environmental Sciences and Management, North West University, Potchefstroom, South Africa
| | - V Lobaskin
- School of Physics, University College Dublin, Dublin, Ireland
| | - I Lynch
- School of Geography, Earth and Environmental Sciences, University of Birmingham, Birmingham, UK
| | - A Federico
- FHAIVE, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Tampere Institute for Advanced Study, Tampere, Finland
| | - D Greco
- FHAIVE, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
- Institute of Biotechnology, Helsinki Institute of Life Sciences (HiLife), University of Helsinki, Helsinki, Finland.
- Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
| |
Collapse
|
5
|
Paassen I, Williams J, Ríos Arceo C, Ringnalda F, Mercer KS, Buhl JL, Moreno N, Federico A, Franke NE, Kranendonk M, Upadhyaya SA, Kerl K, van de Wetering M, Clevers H, Kool M, Hoving EW, Roussel MF, Drost J. Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities. Oncogene 2023; 42:1661-1671. [PMID: 37020038 PMCID: PMC10181938 DOI: 10.1038/s41388-023-02681-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Revised: 03/15/2023] [Accepted: 03/23/2023] [Indexed: 04/07/2023]
Abstract
Atypical teratoid/rhabdoid tumors (ATRTs) represent a rare, but aggressive pediatric brain tumor entity. They are genetically defined by alterations in the SWI/SNF chromatin remodeling complex members SMARCB1 or SMARCA4. ATRTs can be further classified in different molecular subgroups based on their epigenetic profiles. Although recent studies suggest that the different subgroups have distinct clinical features, subgroup-specific treatment regimens have not been developed thus far. This is hampered by the lack of pre-clinical in vitro models representative of the different molecular subgroups. Here, we describe the establishment of ATRT tumoroid models from the ATRT-MYC and ATRT-SHH subgroups. We demonstrate that ATRT tumoroids retain subgroup-specific epigenetic and gene expression profiles. High throughput drug screens on our ATRT tumoroids revealed distinct drug sensitivities between and within ATRT-MYC and ATRT-SHH subgroups. Whereas ATRT-MYC universally displayed high sensitivity to multi-targeted tyrosine kinase inhibitors, ATRT-SHH showed a more heterogeneous response with a subset showing high sensitivity to NOTCH inhibitors, which corresponded to high expression of NOTCH receptors. Our ATRT tumoroids represent the first pediatric brain tumor organoid model, providing a representative pre-clinical model which enables the development of subgroup-specific therapies.
Collapse
Affiliation(s)
- Irene Paassen
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
- Oncode Institute, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
| | - Justin Williams
- Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN, USA
| | - Carla Ríos Arceo
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
- Oncode Institute, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
| | - Femke Ringnalda
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
- Oncode Institute, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
| | - Kimberly Shea Mercer
- Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN, USA
| | - Juliane L Buhl
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
- Oncode Institute, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
| | - Natalia Moreno
- Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany
| | - Aniello Federico
- Hopp Children's Cancer Center (KiTZ), 69120, Heidelberg, Germany
- Division of Pediatric Neurooncology, German Cancer Research Center DKFZ and German Cancer Consortium DKTK, 69120, Heidelberg, Germany
| | - Niels E Franke
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
| | - Mariette Kranendonk
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
| | | | - Kornelius Kerl
- Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany
| | - Marc van de Wetering
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
- Oncode Institute, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
| | - Hans Clevers
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
- Oncode Institute, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
- Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center, 3584 CT, Utrecht, the Netherlands
- Pharma, Research and Early Development (pRED) of F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Marcel Kool
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
- Hopp Children's Cancer Center (KiTZ), 69120, Heidelberg, Germany
- Division of Pediatric Neurooncology, German Cancer Research Center DKFZ and German Cancer Consortium DKTK, 69120, Heidelberg, Germany
| | - Eelco W Hoving
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands
| | - Martine F Roussel
- Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN, USA
| | - Jarno Drost
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands.
- Oncode Institute, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands.
| |
Collapse
|
6
|
Gopisetty A, Federico A, Surdez D, Iddir Y, Zaidi S, Saint-Charles A, Waterfall J, Saberi-Ansari E, Wierzbinska J, Schlicker A, Mack N, Schwalm B, Previti C, Weiser L, Buchhalter I, Böttcher AL, Sill M, Autry R, Estermann F, Jones D, Volckmann R, Zwijnenburg D, Eggert A, Heidenreich O, Iradier F, Jeremias I, Kovar H, Klusmann JH, Debatin KM, Bomken S, Hamerlik P, Hattersley M, Witt O, Chesler L, Mackay A, Gojo J, Cairo S, Schueler J, Schulte J, Geoerger B, Molenaar JJ, Shields DJ, Caron HN, Vassal G, Stancato LF, Pfister SM, Jaeger N, Koster J, Kool M, Schleiermacher G. Abstract 234: ITCC-P4: Genomic profiling and analyses of pediatric patient tumor and patient-derived xenograft (PDX) models for high throughput in vivo testing. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Advancements in state-of-the-art molecular profiling techniques have resulted in better understanding of pediatric cancers and driver events. It has become apparent that pediatric cancers are significantly more heterogeneous than previously thought as evidenced by the number of novel entities and subtypes that have been identified with distinct molecular and clinical characteristics. For most of these newly recognized entities there are extremely limited treatment options available. The ITCC-P4 consortium is an international collaboration between several European academic centers and pharmaceutical companies, with the overall aim to establish a sustainable platform of >400 molecularly well-characterized PDX models of high-risk pediatric cancers, their tumors and matching controls and to use the PDX models for in vivo testing of novel mechanism-of-action based treatments. Currently, 251 models are fully characterized, including 182 brain and 69 non-brain PDX models, representing 112 primary models, 92 relapse, 42 metastasis and 4 progressions under treatment models. Using low coverage whole-genome and whole exome sequencing, somatic mutation calling, DNA copy number and methylation analysis we aim to define genetic features in our PDX models and estimate the molecular fidelity of PDX models compared to their patient tumor. Based on DNA methylation profiling we identified 43 different tumor subgroups within 18 cancer entities. Mutational landscape analysis identified key somatic and germline oncogenic drivers. Ependymoma PDX models displayed the C11orf95-RELA fusion event, YAP1, C11orf95 and RELA structural variants. Medulloblastoma models were driven by MYCN, TP53, GLI2, SUFU and PTEN. High-grade glioma samples showed TP53, ATRX, MYCN and PIK3CA somatic SNVs, along with focal deletions in CDKN2A in chromosome 9. Neuroblastoma models were enriched for ALK SNVs and/or MYCN focal amplification, ATRX SNVs and CDKN2A/B deletions. Tumor mutational burden across entities and copy number analysis was performed to identify allele-specific copy number detection in tumor-normal pairs. Large chromosomal aberrations (deletions, duplications) detected in the PDX models were concurrent with molecular alterations frequently observed in each tumor type -isochromosome 17 was detected in 5 medulloblastoma models, while deletion of chromosome arm 1p or gain of parts of 17q in neuroblastomas which correlate with tumor progression. We observe clonal evolution of somatic variants not only in certain PDX-tumor pairs but also between disease states. The multi-omics approach in this study provides insight into the mutational landscape and patterns of the PDX models thus providing an overview of molecular mechanisms facilitating the identification and prioritization of oncogenic drivers and potential biomarkers for optimal treatment therapies.
Citation Format: Apurva Gopisetty, Aniello Federico, Didier Surdez, Yasmine Iddir, Sakina Zaidi, Alexandra Saint-Charles, Joshua Waterfall, Elnaz Saberi-Ansari, Justyna Wierzbinska, Andreas Schlicker, Norman Mack, Benjamin Schwalm, Christopher Previti, Lena Weiser, Ivo Buchhalter, Anna-Lisa Böttcher, Martin Sill, Robert Autry, Frank Estermann, David Jones, Richard Volckmann, Danny Zwijnenburg, Angelika Eggert, Olaf Heidenreich, Fatima Iradier, Irmela Jeremias, Heinrich Kovar, Jan-Henning Klusmann, Klaus-Michael Debatin, Simon Bomken, Petra Hamerlik, Maureen Hattersley, Olaf Witt, Louis Chesler, Alan Mackay, Johannes Gojo, Stefano Cairo, Julia Schueler, Johannes Schulte, Birgit Geoerger, Jan J. Molenaar, David J. Shields, Hubert N. Caron, Gilles Vassal, Louis F. Stancato, Stefan M. Pfister, Natalie Jaeger, Jan Koster, Marcel Kool, Gudrun Schleiermacher. ITCC-P4: Genomic profiling and analyses of pediatric patient tumor and patient-derived xenograft (PDX) models for high throughput in vivo testing [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 234.
Collapse
Affiliation(s)
- Apurva Gopisetty
- 1German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany
| | - Aniello Federico
- 1German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany
| | - Didier Surdez
- 2INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France; Balgrist University Hospital, Faculty of Medicine, University of Zurich (UZH), Z, Paris, France
| | - Yasmine Iddir
- 2INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France; Balgrist University Hospital, Faculty of Medicine, University of Zurich (UZH), Z, Paris, France
| | - Sakina Zaidi
- 2INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France; Balgrist University Hospital, Faculty of Medicine, University of Zurich (UZH), Z, Paris, France
| | - Alexandra Saint-Charles
- 2INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France; Balgrist University Hospital, Faculty of Medicine, University of Zurich (UZH), Z, Paris, France
| | - Joshua Waterfall
- 2INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France; Balgrist University Hospital, Faculty of Medicine, University of Zurich (UZH), Z, Paris, France
| | - Elnaz Saberi-Ansari
- 2INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France; Balgrist University Hospital, Faculty of Medicine, University of Zurich (UZH), Z, Paris, France
| | - Justyna Wierzbinska
- 3Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany, Berlin, Germany
| | - Andreas Schlicker
- 3Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany, Berlin, Germany
| | - Norman Mack
- 1German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany
| | - Benjamin Schwalm
- 1German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany
| | - Christopher Previti
- 1German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany
| | - Lena Weiser
- 1German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany
| | - Ivo Buchhalter
- 1German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany
| | - Anna-Lisa Böttcher
- 1German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany
| | - Martin Sill
- 1German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany
| | - Robert Autry
- 1German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany
| | - Frank Estermann
- 1German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany
| | - David Jones
- 1German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany
| | - Richard Volckmann
- 4Center for Experimental and Molecular Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands, Amsterdam, Netherlands
| | - Danny Zwijnenburg
- 4Center for Experimental and Molecular Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands, Amsterdam, Netherlands
| | - Angelika Eggert
- 5Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany
| | - Olaf Heidenreich
- 6Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Translational and Clinical Research Institute, Newcastle University and The Great North Children's Hospital, Newcastle upon Tyne, United Kingdom, Utrecht, Netherlands
| | - Fatima Iradier
- 7Eli Lilly and Company, Lilly SAU, Alcobendas, Spain., Alcobendas, Spain
| | - Irmela Jeremias
- 8Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Center for Environmental Health (HMGU), Munich, Germany; Department of Pediatrics, Dr. von Hauner Childrens Hospital, Ludwig Maximilian University of Munich (LMU), Muni, Munich, Germany
| | - Heinrich Kovar
- 9Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria, Vienna, Austria
| | - Jan-Henning Klusmann
- 10Department of Pediatrics I, Martin-Luther-University Halle-Wittenberg, Halle, Germany, Halle, Germany
| | - Klaus-Michael Debatin
- 11Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany, Ulm, Germany
| | - Simon Bomken
- 12Translational and Clinical Research Institute, Newcastle University and The Great North Children's Hospital, Newcastle upon Tyne, United Kingdom, Newcastle upon Tyne, United Kingdom
| | - Petra Hamerlik
- 13AstraZeneca, R&D, Cambridge, United Kingdom, Cambridge, United Kingdom
| | | | - Olaf Witt
- 1German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany
| | - Louis Chesler
- 15Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom, London, United Kingdom
| | - Alan Mackay
- 15Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom, London, United Kingdom
| | - Johannes Gojo
- 16German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, 8. Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria, Vienna, Austria
| | - Stefano Cairo
- 17XenTech, 4 rue Pierre Fontaine, Evry-Courcouronnes, France, Evry-Courcouronnes, France
| | - Julia Schueler
- 18Charles River Germany, Freiburg, Germany, Freiburg, Germany
| | - Johannes Schulte
- 5Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany
| | - Birgit Geoerger
- 19INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, F-94805 France, Villejuif, France
| | - Jan J. Molenaar
- 20Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands, Utrecht, Netherlands
| | - David J. Shields
- 21Pfizer Centers for Therapeutic Innovation, Pfizer Inc., New York, USA, New York, NY
| | | | - Gilles Vassal
- 23Gustave Roussy Cancer Campus, INSERM U1015, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France;22. European consortium for Innovative Therapies for Children with Cancer (ITCC), Paris, France, Paris, France
| | | | - Stefan M. Pfister
- 1German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany
| | - Natalie Jaeger
- 1German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany
| | - Jan Koster
- 4Center for Experimental and Molecular Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands, Amsterdam, Netherlands
| | - Marcel Kool
- 25German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands, Heidelberg, Germany
| | - Gudrun Schleiermacher
- 2INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France; Balgrist University Hospital, Faculty of Medicine, University of Zurich (UZH), Z, Paris, France
| |
Collapse
|
7
|
Steinfass T, Poelchen J, Sun Q, Mastrogiulio G, Novak D, Vierthaler M, Pardo S, Federico A, Hüser L, Hielscher T, Carretero R, Offringa R, Altevogt P, Umansky V, Utikal J. Secretogranin II influences the assembly and function of MHC class I in melanoma. Exp Hematol Oncol 2023; 12:29. [PMID: 36906639 PMCID: PMC10007832 DOI: 10.1186/s40164-023-00387-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2022] [Accepted: 02/12/2023] [Indexed: 03/13/2023] Open
Abstract
Melanoma is the deadliest form of skin cancer showing rising incidence over the past years. New insights into the mechanisms of melanoma progression contributed to the development of novel treatment options, such as immunotherapies. However, acquiring resistance to treatment poses a big problem to therapy success. Therefore, understanding the mechanisms underlying resistance could improve therapy efficacy. Correlating expression levels in tissue samples of primary melanoma and metastases revealed that secretogranin 2 (SCG2) is highly expressed in advanced melanoma patients with poor overall survival (OS) rates. By conducting transcriptional analysis between SCG2-overexpressing (OE) and control melanoma cells, we detected a downregulation of components of the antigen presenting machinery (APM), which is important for the assembly of the MHC class I complex. Flow cytometry analysis revealed a downregulation of surface MHC class I expression on melanoma cells that showed resistance towards the cytotoxic activity of melanoma-specific T cells. IFNγ treatment partially reversed these effects. Based on our findings, we suggest that SCG2 might stimulate mechanisms of immune evasion and therefore be associated with resistance to checkpoint blockade and adoptive immunotherapy.
Collapse
Affiliation(s)
- Tamara Steinfass
- Skin Cancer Unit, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,Faculty of Biosciences, Ruprecht Karl University of Heidelberg, Heidelberg, Germany
| | - Juliane Poelchen
- Skin Cancer Unit, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,Faculty of Biosciences, Ruprecht Karl University of Heidelberg, Heidelberg, Germany
| | - Qian Sun
- Skin Cancer Unit, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,Faculty of Biosciences, Ruprecht Karl University of Heidelberg, Heidelberg, Germany
| | - Giovanni Mastrogiulio
- Joint Immunotherapeutics Laboratory, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany
| | - Daniel Novak
- Skin Cancer Unit, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
| | - Marlene Vierthaler
- Skin Cancer Unit, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,Faculty of Biosciences, Ruprecht Karl University of Heidelberg, Heidelberg, Germany
| | - Sandra Pardo
- Skin Cancer Unit, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,Faculty of Biosciences, Ruprecht Karl University of Heidelberg, Heidelberg, Germany
| | - Aniello Federico
- Skin Cancer Unit, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany
| | - Laura Hüser
- Skin Cancer Unit, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,Division of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD, 21205, USA
| | - Thomas Hielscher
- Division of Biostatistics, German Cancer Research Center (DKFZ), INF 581, 69120, Heidelberg, Germany
| | - Rafael Carretero
- Joint Immunotherapeutics Laboratory, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany
| | - Rienk Offringa
- Joint Immunotherapeutics Laboratory, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany.,Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany.,Department of Surgery, University Hospital Heidelberg, INF 420, 69120, Heidelberg, Germany
| | - Peter Altevogt
- Skin Cancer Unit, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
| | - Viktor Umansky
- Skin Cancer Unit, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.,Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Ruprecht Karl University of Heidelberg, Ludolf-Krehl-Straße 13-17, 68167, Mannheim, Germany
| | - Jochen Utikal
- Skin Cancer Unit, German Cancer Research Center (DKFZ), INF 280, 69120, Heidelberg, Germany. .,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. .,DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
| |
Collapse
|
8
|
Okonechnikov K, Federico A, Schrimpf D, Sievers P, Sahm F, Koster J, Jones DTW, von Deimling A, Pfister SM, Kool M, Korshunov A. Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses. Acta Neuropathol Commun 2023; 11:7. [PMID: 36635768 PMCID: PMC9837941 DOI: 10.1186/s40478-023-01504-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Accepted: 12/27/2022] [Indexed: 01/13/2023] Open
Abstract
Nowadays medulloblastoma (MB) tumors can be treated with risk-stratified approaches with up to 80% success rate. However, disease relapses occur in approximately 30% of patients and successful salvage treatment strategies at relapse remain scarce. Acquired copy number changes or TP53 mutations are known to occur frequently in relapses, while methylation profiles usually remain highly similar to those of the matching primary tumors, indicating that in general molecular subgrouping does not change during the course of the disease. In the current study, we have used RNA sequencing data to analyze the transcriptome profiles of 43 primary-relapse MB pairs in order to identify specific molecular features of relapses within various tumor groups. Gene variance analysis between primary and relapse samples demonstrated the impact of age in SHH-MB: the changes in gene expression relapse profiles were more pronounced in the younger patients (< 10 years old), which were also associated with increased DNA aberrations and somatic mutations at relapse probably driving this effect. For Group 3/4 MB transcriptome data analysis uncovered clear sets of genes either active or decreased at relapse that are significantly associated with survival, thus could be potential predictive markers. In addition, deconvolution analysis of bulk transcriptome data identified progression-associated differences in cell type enrichment. The proportion of undifferentiated progenitors increased in SHH-MB relapses with a concomitant decrease of differentiated neuron-like cells, while in Group 3/4 MB relapses cell cycle activity increases and differentiated neuron-like cells proportion decreases as well. Thus, our findings uncovered significant transcriptome changes in the molecular signatures of relapsed MB and could be potentially useful for further clinical purposes.
Collapse
Affiliation(s)
- Konstantin Okonechnikov
- grid.510964.fHopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany ,grid.7497.d0000 0004 0492 0584Division of Pediatric Neuro-Oncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Aniello Federico
- grid.510964.fHopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany ,grid.7497.d0000 0004 0492 0584Division of Pediatric Neuro-Oncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Daniel Schrimpf
- grid.7497.d0000 0004 0492 0584Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany ,grid.5253.10000 0001 0328 4908Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany
| | - Philipp Sievers
- grid.7497.d0000 0004 0492 0584Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany ,grid.5253.10000 0001 0328 4908Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany
| | - Felix Sahm
- grid.510964.fHopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany ,grid.7497.d0000 0004 0492 0584Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany ,grid.5253.10000 0001 0328 4908Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany
| | - Jan Koster
- grid.7177.60000000084992262Center for Experimental and Molecular Medicine, Amsterdam University Medical Centers, University of Amsterdam and Cancer Center Amsterdam, Amsterdam, The Netherlands
| | - David T. W. Jones
- grid.510964.fHopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany ,grid.7497.d0000 0004 0492 0584Division of Pediatric Glioma Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Andreas von Deimling
- grid.510964.fHopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany ,grid.7497.d0000 0004 0492 0584Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany ,grid.5253.10000 0001 0328 4908Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany
| | - Stefan M. Pfister
- grid.510964.fHopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany ,grid.7497.d0000 0004 0492 0584Division of Pediatric Neuro-Oncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany ,grid.5253.10000 0001 0328 4908Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany
| | - Marcel Kool
- grid.510964.fHopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany ,grid.7497.d0000 0004 0492 0584Division of Pediatric Neuro-Oncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany ,grid.487647.ePrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
| | - Andrey Korshunov
- grid.510964.fHopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany ,grid.7497.d0000 0004 0492 0584Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany ,grid.5253.10000 0001 0328 4908Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany
| |
Collapse
|
9
|
Cozzolino R, De Giulio B, Martignetti A, Forte G, Dallio M, Romeo M, Scognamiglio F, Ventriglia L, Stocchero M, Federico A. Urinary volatile Organic compounds in non-alcoholic fatty liver disease (NAFLD), type two diabetes mellitus (T2DM) and NAFLD-T2DM coexistence. Metabolomics 2022; 18:98. [PMID: 36441279 DOI: 10.1007/s11306-022-01960-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2022] [Accepted: 11/18/2022] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Accumulating evidence have shown a significant correlation between urinary volatile organic compounds (VOCs) profile and the manifestation of several physiological and pathological states, including liver diseases. Previous studies have investigated the urinary metabolic signature as a non-invasive tool for the early discrimination between non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), which nowadays represents one of the most important challenges in this context, feasible only by carrying out liver biopsy. OBJECTIVES The aim of the study was to investigate the differences in the urinary VOCs profiles of non-alcoholic fatty liver disease (NAFLD) patients, diabetes mellitus (T2DM) subjects and NAFLD/T2DM patients. METHODS Headspace solid-phase microextraction (HS-SPME) coupled with gas chromatography-mass spectrometry (GC-MS) was applied to profile the urinary VOCs. Urine samples were analysed both under acid and alkaline conditions, to obtain a range of urinary volatiles with different physicochemical properties. RESULTS Urinary VOCs profiles of 13 NAFLD patients, 13 T2DM subjects and 13 NAFLD/T2DM patients were investigated by multivariate and univariate data analysis techniques which allowed to identify 21 volatiles under alkaline conditions able to describe the NAFLD/T2DM group concerning the other two groups. CONCLUSION Our results suggest that VOCs signatures can improve the knowledge of the pathological condition where NAFLD coexists with T2DM and discovering new features that are not simply the sum of the two diseases. These preliminary findings may be considered as hypothesis-generating, to be clearly confirmed by larger prospective investigations.
Collapse
Affiliation(s)
- Rosaria Cozzolino
- Institute of Food Science, National Research Council (CNR), via Roma 64, 83100, Avellino, Italy.
| | - Beatrice De Giulio
- Institute of Food Science, National Research Council (CNR), via Roma 64, 83100, Avellino, Italy.
| | - A Martignetti
- Institute of Food Science, National Research Council (CNR), via Roma 64, 83100, Avellino, Italy
| | - G Forte
- Institute of Food Science, National Research Council (CNR), via Roma 64, 83100, Avellino, Italy
| | - M Dallio
- Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138, Naples, Italy
| | - M Romeo
- Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138, Naples, Italy
| | - F Scognamiglio
- Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138, Naples, Italy
| | - L Ventriglia
- Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138, Naples, Italy
| | - M Stocchero
- Department of Women's and Children's Health, University of Padua, Padua, Italy
| | - A Federico
- Institute of Food Science, National Research Council (CNR), via Roma 64, 83100, Avellino, Italy
| |
Collapse
|
10
|
Gopisetty A, Federico A, Surdez D, Saberi-Ansari E, Iddir Y, Saint-Charles A, Waterfall J, Wierzbinska J, Schlicker A, Mack N, Schwalm B, Jones DT, Gojo J, Chesler L, Vassal G, Stancato L, Koster J, Molenaar JJ, Jaeger N, Schleiermacher G, Pfister S, Kool M. EPCO-47. ITCC-P4: GENOMIC PROFILING AND ANALYSES OF PEDIATRIC PATIENT TUMOR AND PATIENT-DERIVED XENOGRAFT (PDX) MODELS FOR HIGH THROUGHPUT IN VIVO TESTING. Neuro Oncol 2022. [PMCID: PMC9660314 DOI: 10.1093/neuonc/noac209.481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Advancements in state-of-the-art molecular profiling techniques has resulted in better understanding of pediatric cancers and their drivers. Conversely, it also became apparent that pediatric cancers are much more heterogeneous than previously thought. Many new types and subtypes of pediatric cancers have been identified with distinct molecular and clinical characteristics. However, for most newly recognized entities there is no specific treatment available yet. The ITCC-P4 consortium is a collaboration between many academic centers across Europe and several pharmaceutical companies involved in preclinical testing, with the overall aim to establish a sustainable platform of >400 molecularly well-characterized PDX models of high-risk pediatric cancers and to use them for in vivo testing of novel mechanism-of-action based treatments. Currently, 340 models are fully established, including 87 brain and 253 non-brain tumor models, together representing different tumor types both from primary (113) and relapsed (92)/metastatic disease (42). 252 of these models have been fully molecularly characterized, representing 18 pediatric cancer entities and 43 different subtypes. Using low coverage whole-genome and whole exome sequencing, somatic mutation calling, DNA copy number, transcriptome analysis and methylation profiling we have observed that the molecular profile of most PDX models closely mimics their original tumors. Clonal evolution of somatic variants was only observed in some PDX-tumor pairs or so between disease states. Somatic copy number variant analysis highlights specific alterations for instance MYB, MYC, MYCN, NTRK3, PTEN loss differently distributed between PDX-patient tumor pairs in high-grade gliomas. Overall, our results show that we have established >250 PDX models of solid pediatric cancers, that well represents the disease spectrum and that is currently being used for in vivo testing of standard of care drugs and targeted small molecules. Treatment responses will be directly linked to molecular data to identify potential biomarkers for prioritization or deprioritization of individual, patient-specific specific drugs.
Collapse
Affiliation(s)
- Apurva Gopisetty
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg , Baden-Wurttemberg , Germany
| | - Aniello Federico
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg , Baden-Wurttemberg , Germany
| | - Didier Surdez
- INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France , Paris , France
| | - Elnaz Saberi-Ansari
- INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France , Paris , France
| | - Yasmine Iddir
- INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France , Paris , France
| | - Alexandra Saint-Charles
- INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France , Paris , France
| | - Joshua Waterfall
- INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France , Paris , France
| | - Justyna Wierzbinska
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany , Berlin , Germany
| | - Andreas Schlicker
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany , Berlin , Germany
| | - Norman Mack
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany , Heidelberg , Germany
| | - Benjamin Schwalm
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany , Heidelberg , Germany
| | - David T Jones
- Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | | | - Louis Chesler
- Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom , London , United Kingdom
| | - Gilles Vassal
- Department of Clinical Research, Gustave Roussy, Villejuif, France , Paris , France
| | | | - Jan Koster
- Department of Oncogenomics, Amsterdam University Medical Centre, Amsterdam, the Netherlands , Amsterdam , Netherlands
| | - Jan J Molenaar
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands , Utrecht , Netherlands
| | - Natalie Jaeger
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany , Heidelberg , Germany
| | - Gudrun Schleiermacher
- INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France , Paris , France
| | - Stefan Pfister
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany , Heidelberg , Germany
| | - Marcel Kool
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany , Heidelberg , Germany
| |
Collapse
|
11
|
D'Avino A, Aloi G, Argo G, Bozza L, Canale P, Carlomagno F, Carpino A, Castaldo E, Castiglione O, Chianese P, Cioffi L, Coppola G, Costigliola C, D'Onofrio A, de Franchis R, De Giovanni M, De Magistris T, De Prosperis A, Ercolini P, Esposito A, Federico A, Gasparini N, Granata M, Iasevoli S, Losco R, Maiello R, Russo S, Sassi R, Vascone A, Vallefuoco G. Family Pediatrician and Public Health collaboration, an alliance to increase vaccination coverage: an experience with MenB vaccination in Italy. Ann Ig 2022; 34:415-420. [PMID: 34882165 DOI: 10.7416/ai.2021.2490] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
BACKGROUND Invasive Meningococcal Disease is a severe disease mainly affecting infants and young children. Most infections are caused by serogroups A, B, C, W, X, and Y. In the last 10 years, serogroup B has been the main cause of Invasive Meningococcal Disease in Europe. Recent data resulting from an observational study conducted in Italy show a significant reduction in the number of Invasive Meningococcal Disease cases due to Neisseria meningitidis B after the introduction of vaccine 4CMenB. Thus, the Naples Team of Federation of Italian Primary Care Pediatricians and the Public Health Department started an active collaboration focused on vaccination process management (named "Progetto Via") with the aim of increasing Meningococcal B vaccination coverage. STUDY DESIGN Source of data is the regional platform "GE.VA.". Every Primary care Pediatrician uses daily to record vaccination activity. This platform is integrated with data entered by operators of the District/Vaccination Center. METHODS Time: January 2019 - December 2019. The Federation of Italian Primary Care Pediatricians/Naples organized a meeting to identify six coordinators. The pediatricians could choose to counsel in their own offices and send children to the vaccination center or to counsel and vaccinate directly in their own clinics. RESULTS A total of 78 pediatricians took part in the project: 46 did only counseling and 32 did both counseling and vaccination in their medical clinic. Data obtained show an overall average vaccination coverage growth of about 13% in the first 4 months of the survey, and a further growth of about 11% in the following seven months, with a total growth in the entire period of 24%. The pediatricians' counseling is essential to recover non-compliant subjects, considering both the relationship of trust with the families and the visits already scheduled as an ideal moment for vaccinations' status check. CONCLUSIONS The project highlights how an effective collaboration between family pediatricians and the Local Health Authority becomes valuable in getting closer to reach the Ministerial goal of 95%. Vaccination coverage increased significantly when family pediatricians supported the activity of vaccine centers in distress in many regional situations. The trust relationship, the hourly availability and the capillary network of family pediatricians' clinics were key elements for the success of this project and were also recognized by parents.
Collapse
Affiliation(s)
- A D'Avino
- Italian Federation of Primary Care Pediatricians (FIMP), National Vice President, Provincial Secretary of Naples, Naples, Italy
| | - G Aloi
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - G Argo
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - L Bozza
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - P Canale
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - F Carlomagno
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - A Carpino
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - E Castaldo
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - O Castiglione
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - P Chianese
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - L Cioffi
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - G Coppola
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - C Costigliola
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - A D'Onofrio
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - R de Franchis
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - M De Giovanni
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - T De Magistris
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - A De Prosperis
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - P Ercolini
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - A Esposito
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - A Federico
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - N Gasparini
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - M Granata
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - S Iasevoli
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - R Losco
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - R Maiello
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - S Russo
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - R Sassi
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - A Vascone
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| | - G Vallefuoco
- Italian Federation of Primary Care Pediatricians (FIMP), Italy
| |
Collapse
|
12
|
de Franchis R, Bozza L, Canale P, Chiacchio M, Cortese P, D’Avino A, De Giovanni M, Iacovo MD, D’Onofrio A, Federico A, Gasparini N, Iaccarino F, Romano G, Spadaro R, Tedesco M, Vitiello G, Antignani A, Auricchio S, Valentino V, De Filippis F, Ercolini D, Bruzzese D. The Effect of Weaning with Adult Food Typical of the Mediterranean Diet on Taste Development and Eating Habits of Children: A Randomized Trial. Nutrients 2022; 14:nu14122486. [PMID: 35745216 PMCID: PMC9227033 DOI: 10.3390/nu14122486] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 06/06/2022] [Accepted: 06/13/2022] [Indexed: 11/16/2022] Open
Abstract
Mediterranean Diet (Med Diet) is one of the healthiest dietary patterns. We aimed to verify the effects of weaning (i.e., the introduction of solid foods in infants previously fed only with milk) using adult foods typical of Med Diet on children eating habits, and on the microbiota composition. A randomized controlled clinical trial on 394 healthy infants randomized in a 1:1 ratio in a Med Diet group weaned with fresh; seasonal and tasty foods of Med Diet and control group predominantly weaned with industrial baby foods. The primary end point was the percentage of children showing a good adherence to Med Diet at 36 months. Secondary end points were mother’s changes in adherence to Med Diet and differences in children gut microbiota. At 36 months, children showing a good adherence to Med Diet were 59.3% in the Med Diet group and 34.3% in the control group (p < 0.001). An increase in adherence to the Med Diet was observed in the mothers of the Med Diet group children (p < 0.001). At 4 years of age children in the Med Diet group had a higher gut microbial diversity and a higher abundance of beneficial taxa. A Mediterranean weaning with adult food may become a strategy for early nutritional education, to develop a healthy microbiota, to prevent inflammatory chronic diseases and to ameliorate eating habits in children and their families.
Collapse
Affiliation(s)
- Raffaella de Franchis
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
- Correspondence:
| | - Luigi Bozza
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
| | - Pasquale Canale
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
| | - Maria Chiacchio
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
| | - Paolo Cortese
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
| | - Antonio D’Avino
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
| | - Maria De Giovanni
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
| | - Mirella Dello Iacovo
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
| | - Antonietta D’Onofrio
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
| | - Aniello Federico
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
| | - Nicoletta Gasparini
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
| | - Felicia Iaccarino
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
| | - Giuseppe Romano
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
| | - Raffaella Spadaro
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
| | - Mariangela Tedesco
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
| | - Giuseppe Vitiello
- Italian Federation of Maedical Paediatrics (FIMP), 80142 Naples, Italy; (L.B.); (P.C.); (M.C.); (P.C.); (A.D.); (M.D.G.); (M.D.I.); (A.D.); (A.F.); (N.G.); (F.I.); (G.R.); (R.S.); (M.T.); (G.V.)
| | - Angelo Antignani
- Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy;
| | - Salvatore Auricchio
- European Laboratory for the Investigation of Food-Induced Diseases, Department of Medical Translational Sciences, University of Naples Federico II, 80131 Naples, Italy;
| | - Vincenzo Valentino
- Department of Agricultural Sciences, University of Naples Federico II, 80055 Portici, Italy; (V.V.); (F.D.F.); (D.E.)
| | - Francesca De Filippis
- Department of Agricultural Sciences, University of Naples Federico II, 80055 Portici, Italy; (V.V.); (F.D.F.); (D.E.)
- Task Force on Microbiome Studies, University of Naples Federico II, 80100 Naples, Italy
| | - Danilo Ercolini
- Department of Agricultural Sciences, University of Naples Federico II, 80055 Portici, Italy; (V.V.); (F.D.F.); (D.E.)
- Task Force on Microbiome Studies, University of Naples Federico II, 80100 Naples, Italy
| | - Dario Bruzzese
- Department of Public Health, University of Naples Federico II, 80131 Naples, Italy;
| |
Collapse
|
13
|
Feyerabend S, Rieckmann T, Riepen B, Oetting A, Christiansen S, Schoof M, Hardt A, Köcher S, Neumann J, Schwarz R, Mack N, Schwalm B, Federico A, Milde T, Kool M, Schüller U, Rutkowski S, Petersen C, Rothkamm K, Mynarek M, Struve N. MEDB-50. Assessment of cellular radiosensitivity and DNA repair in medulloblastoma cell lines and patient-derivded xenograft slice cultures. Neuro Oncol 2022. [PMCID: PMC9164929 DOI: 10.1093/neuonc/noac079.424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Medulloblastoma (WHO grade 4) is the most common malignant brain tumor of childhood. Despite the high importance of radiotherapy for disease control, the mechanisms underlying response and resistance to radiotherapy are incompletely understood. Therefore, we assessed the radiosensitivity and DNA repair capacity of medulloblastoma cell lines in-vitro and of patient-derived xenograft (PDX) models ex-vivo. Cell survival after irradiation of seven medulloblastoma cell lines displaying different subgroups was assessed via colony formation assay (DAOY, UW228, UW473, SJMM4, ONS-76, HDMB-03, D283). The ONS-76 and the mouse SJMM4 cell line were the most radioresistant strains (surviving fraction after 6 Gy (SF6): 0.33 and 0.31, respectively), followed by UW473, UW 228 and DAOY cells (SF6 0.16-0.21). The non-WNT/non-SHH-activated cell lines HDMB-03 and D283 cells demonstrated profoundly higher cellular radiosensitivity (SF6 <0.05). Analysis of residual (24h after irradiation) DNA double-strand breaks (DSB) as assessed by co-localized γH2AX/53BP1-foci demonstrated a significant correlation between DSB repair capacity and cellular survival. To use a more reliable pre-clinical model for medulloblastoma, we further examined DNA repair foci in ex-vivo irradiated slice cultures of PDX models MED-113 (SHH) and NCH2194 & HT028 (Gr. 3). Immunofluorescence analyses of frozen sections demonstrated non-hypoxic (pimonidazole-negative) and proliferating (EdU-positive) cells at the outer rim of the tumor slices. Two hours after irradiation all three PDX models showed a strong increase in 53BP1-foci, clearly indicating DNA damage induction. Most radiation-induced DSB were repaired after 24h. In a first radiosensitization approach, we treated the HT028 model with the PARP inhibitor olaparib (1µM ± 2Gy irradiation). Twenty-four hours after treatment the sample displayed a strong increase in the amount and size of 53BP1-foci, indicating compromised DNA repair. Further in-vitro and ex-vivo investigations with the aim to predict individual radiosensitivity and effective radiosensitization strategies are ongoing.
Collapse
Affiliation(s)
- Simon Feyerabend
- Department of Radiotherapy, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Thorsten Rieckmann
- Department of Radiotherapy, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
- Department of Otolaryngology and Head and Neck Surgery, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Britta Riepen
- Department of Radiotherapy, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Agnes Oetting
- Department of Radiotherapy, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
- Department of Otolaryngology and Head and Neck Surgery, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Sabrina Christiansen
- Department of Radiotherapy, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
- Department of Otolaryngology and Head and Neck Surgery, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Melanie Schoof
- Research Institute Children’s Cancer Center Hamburg , Hamburg , Germany
- Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Annika Hardt
- Department of Radiotherapy, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Sabrina Köcher
- Department of Radiotherapy, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Julia Neumann
- Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf , Hamburg , Germany
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Rudolf Schwarz
- Department of Radiotherapy, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Norman Mack
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Benjamin Schwalm
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Aniello Federico
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Till Milde
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Department of Pediatric Oncology, Hematology and Immunology , Heidelberg , Germany
| | - Marcel Kool
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Ulrich Schüller
- Research Institute Children’s Cancer Center Hamburg , Hamburg , Germany
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Stefan Rutkowski
- Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Cordula Petersen
- Department of Radiotherapy, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Kai Rothkamm
- Department of Radiotherapy, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Martin Mynarek
- Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
- Mildred Scheel Cancer Career Center HaTriCS, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Nina Struve
- Department of Radiotherapy, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
- Mildred Scheel Cancer Career Center HaTriCS, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| |
Collapse
|
14
|
Thomas C, Federico A, Bens S, Hellström M, Casar-Borota O, Kordes U, Neumann JE, Dottermusch M, Rodriguez FE, Lo AC, Cheng S, Hendson G, Hukin J, Hartmann C, Koch A, Capper D, Siebert R, Paulus W, Nemes K, Johann PD, Frühwald MC, Kool M, Hasselblatt M. ATRT-07. Low-grade diffusely infiltrative tumor, SMARCB1-mutant: a clinical and histopathological distinct entity showing epigenetic similarity with ATRT-MYC. Neuro Oncol 2022. [PMCID: PMC9165080 DOI: 10.1093/neuonc/noac079.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Most atypical teratoid/rhabdoid tumors (ATRTs) occur in infants, but children and adolescents may also be affected. ATRTs occurring in older patients often comprise the molecular subgroup ATRT-MYC. Recently, central nervous system low-grade diffusely infiltrative tumor with INI1 deficiency (CNS LGDIT-INI1) has been described as a rare low-grade lesion (Nobusawa et al. Am J Surg Pathol 2020;44:1459-1468). Little is known on the molecular relationship of CNS LGDIT-INI1 and ATRT. We therefore further explored a series of six CNS LGDIT-INI1. The median age of the four males and two females was 16 years (range: 10-28 years). All tumors were of supratentorial location and showed low to moderate cellularity, diffuse growth of inconspicuous small SMARCB1-deficient tumor cells and reactive pleomorphic neuronal and glial cells with retained SMARCB1-staining in the background. In addition, two cases also displayed a high-grade rhabdoid component. After DNA isolation, purification and bisulfite conversion, samples were subjected to DNA methylation profiling (MethylationEPIC BeadChip array). Using DNA methylation-based classification and the Heidelberg Brain Tumor Classifier (version v11b4), all tumors were classified as ATRT-MYC (median calibrated score: 0.97). On t-SNE analysis, DNA methylation profiles grouped closely together in proximity to ATRT-MYC. Follow-up information was available for four cases (including the two cases with a high-grade component). Patients received heterogeneous treatments (including chemotherapy according to AT/RT protocols) and experienced stable disease or complete remission after an observation time of three to 56 months. In conclusion, CNS LGDIT-INI1 is a clinically and histologically distinct entity with relatively favorable outcome. Nevertheless, epigenetic similarity with ATRT-MYC and the potential of malignant progression warrants close follow-up examinations. In line with recent developments of WHO nomenclature, we propose to refer to these tumors as “low-grade diffusely infiltrative tumor, SMARCB1-mutant”.
Collapse
Affiliation(s)
- Christian Thomas
- Institute of Neuropathology, University Hospital Münster , Münster , Germany
| | - Aniello Federico
- Hopp Children′s Cancer Center (KiTZ) , Heidelberg , Germany
- Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Susanne Bens
- Institute of Human Genetics, Ulm University & Ulm University Medical Center , Ulm , Germany
| | - Mats Hellström
- Dept. of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University , Uppsala , Sweden
| | - Olivera Casar-Borota
- Dept. of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University , Uppsala , Sweden
- Dept. of Clinical Pathology, Uppsala University Hospital , Uppsala , Sweden
| | - Uwe Kordes
- Dept. of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Julia E Neumann
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
- Center for Molecular Neurobiology Hamburg (ZMNH), University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Matthias Dottermusch
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
- Center for Molecular Neurobiology Hamburg (ZMNH), University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Fausto E Rodriguez
- Dept. of Pathology, The Johns Hopkins University School of Medicine , Baltimore, MD , USA
| | - Andrea C Lo
- Radiation Oncology, British Columbia Cancer and University of British Columbia , Vancouver, BC , Canada
| | - Sylvia Cheng
- Division of Hematology, Oncology & BMT, Department of Pediatrics, University of British Columbia , Vancouver, BC , Canada
| | - Glenda Hendson
- Dept. of Pathology, BC Women and Children's Hospital , Vancouver, BC , Canada
| | - Juliette Hukin
- Division of Hematology, Oncology & BMT, Department of Pediatrics, University of British Columbia , Vancouver, BC , Canada
| | - Christian Hartmann
- Dept. of Neuropathology, Institute of Pathology, Hannover Medical School , Hannover , Germany
| | - Arend Koch
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Dept. of Neuropathology , Berlin , Germany
| | - David Capper
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Dept. of Neuropathology , Berlin , Germany
- German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | - Reiner Siebert
- Institute of Human Genetics, Ulm University & Ulm University Medical Center , Ulm , Germany
| | - Werner Paulus
- Institute of Neuropathology, University Hospital Münster , Münster , Germany
| | - Karolina Nemes
- Swabian Children’s Cancer Center, Paediatric and Adolescent Medicine, University Medical Center Augsburg , Augsburg , Germany
| | - Pascal D Johann
- Swabian Children’s Cancer Center, Paediatric and Adolescent Medicine, University Medical Center Augsburg , Augsburg , Germany
| | - Michael C Frühwald
- Swabian Children’s Cancer Center, Paediatric and Adolescent Medicine, University Medical Center Augsburg , Augsburg , Germany
| | - Marcel Kool
- Hopp Children′s Cancer Center (KiTZ) , Heidelberg , Germany
- Princess Máxima Center for Pediatric Oncology , Utrecht , Netherlands
| | - Martin Hasselblatt
- Institute of Neuropathology, University Hospital Münster , Münster , Germany
| |
Collapse
|
15
|
Federico A, Okonechnikov K, Carmona EB, Lammers JAS, Kranendonk MEG, Gojo J, Englinger B, Jiang L, Nierkens S, Calkoen FGJ, van der Lugt J, Filbin MG, Jäger N, Pfister SM, Kool M. EPEN-08. Single-cell transcriptome analysis defines a tumor-supportive microenvironment and tumor-stroma crosstalk in pediatric ependymoma and medulloblastoma. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac079.145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Brain tumors are the leading cause of disease-related death in childhood and strong efforts are required to develop innovative and efficient therapeutic strategies for patients with high-risk disease. Key critical factor of pediatric brain tumors is their molecular heterogeneity; one of the aspects that contributes to such heterogeneity is the intrinsic capacity of the tumor cells to organize, shape and exploit the surrounding brain tumor microenvironment (TME) to sustain tumor growth and malignant progression. TME was proved to play a crucial role in several malignancies, but in pediatric brain malignancies this has not been fully elucidated yet. Here, we aimed at characterizing the TME cell populations and their contributions in ependymoma and medulloblastoma, two of the most common pediatric brain tumor entities. Single-cell transcriptome analysis (n=65 ependymomas; n=39 medulloblastomas) of publicly available tumor datasets, as well as newly generated data of primary tumors and matching patient-derived tumor xenografts (PDX), showed an extensive heterogeneity of TME cell types with distinctive expression signatures. Amongst the identified TME populations, analysis revealed pro-inflammatory and proliferating myeloid cells, tumor-infiltrating lymphocytes, active regulatory T cells and vascular progenitor cells. Comparative analysis between primary and PDX tumors showed that tumor cells stimulated the host microenvironment, which in turn exhibited tumor-associated stromal signatures. Applying a deconvolution method, using our single cell data as reference, on a bulk tumor cohort including PFA ependymomas with different degree of immune infiltration, we observed an enrichment of polarized macrophages and microglia cells in tumor with high infiltration. Next, we identified TME markers involved in tumor-supportive functions, such as immune suppression (TIGIT, FOXP3, BCL2, CD19, ICAM2), pro-inflammatory stimuli (CCL3, CCL4, IL1B, GPNMB), extracellular matrix remodeling (COL4A1) and angiogenic processes (ANGPT2). TME markers with emerging role in ependymoma and medulloblastoma can be considered as possible targets for tailored and more effective anti-tumor therapeutic strategies.
Collapse
Affiliation(s)
- Aniello Federico
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center , Heidelberg , Germany
| | - Konstantin Okonechnikov
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center , Heidelberg , Germany
| | - Enrique Blanco Carmona
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center , Heidelberg , Germany
| | | | | | - Johannes Gojo
- Hopp Children’s Cancer Center , Heidelberg , Germany
- Medical University of Vienna , Vienna , Austria
| | - Bernhard Englinger
- Dana-Farber Boston Children’s Cancer and Blood Disorders Center , Boston , USA
- Broad Institute of Harvard and MIT , Cambridge , USA
| | - Li Jiang
- Dana-Farber Boston Children’s Cancer and Blood Disorders Center , Boston , USA
- Broad Institute of Harvard and MIT , Cambridge , USA
| | | | | | | | - Mariella G Filbin
- Dana-Farber Boston Children’s Cancer and Blood Disorders Center , Boston , USA
- Broad Institute of Harvard and MIT , Cambridge , USA
| | - Natalie Jäger
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center , Heidelberg , Germany
| | - Stefan M Pfister
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center , Heidelberg , Germany
| | - Marcel Kool
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center , Heidelberg , Germany
| |
Collapse
|
16
|
Odé Z, Maas J, Roosen M, Stathi P, Federico A, Mack N, Schwalm B, Bunt J, Kool M. MEDB-52. Organoids as preclinical models to improve and personalize disease outcome for sonic hedgehog medulloblastoma. Neuro Oncol 2022. [PMCID: PMC9164751 DOI: 10.1093/neuonc/noac079.426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Four main medulloblastoma (MB) molecular subgroups are known, including the sonic hedgehog (SHH) subgroup, which represents ~25% of MB cases. The 5-year overall survival of SHH-MB is ~80%. However, survival between patients is highly diverse and dependent on the driver mutation(s) of the tumor. Patients with TP53 mutated tumors (often accompanied with MYCN and/or GLI2 amplifications) don’t respond well to current therapies and have a 10-year overall survival below 20%. Therefore, there is a need for new and more tailored therapies for these patients. In this study we aim to screen patient-derived organoid models of TP53-mutated SHH MB with a library of ~200 different compounds. We have optimized the cultures of two PDX-derived and one patient-derived organoid line in vitro. The lines will be screened in a high-throughput manner and the best hits and combinations will be validated in corresponding in vivo PDX models. To further assess the role of specific mutations in therapy outcome of TP53-mutated SHH MB, cerebellar organoids generated from human iPSCs were genetically modified with overexpression of dominant-negative P53 (DNP53) alone or in combination with MYCN and/or GLI2. Introduction of DNP53 and MYCN overexpression in cerebellar organoids at day 28/35 leads to the outgrowth of a Ki67-positive proliferating mass after three weeks, indicating tumor growth. Further analyses are ongoing to see how they match SHH-MB patient tumors. These genetically engineered organoid models may elucidate the role of specific mutations in therapy response and/or resistance. In addition, as tumors in these genetically engineered cerebellar organoids arise in a microenvironment of normal cerebellar cell types, initial safety of drugs on cerebellar cells can be assessed. In conclusion, different organoid models of TP53-mutated SHH MB will enable us to find more effective treatments and to better understand how to treat patients with different mutation combinations.
Collapse
Affiliation(s)
- Zelda Odé
- Princess Máxima Center for pediatric oncology , Utrecht , Netherlands
| | - Joris Maas
- Princess Máxima Center for pediatric oncology , Utrecht , Netherlands
| | - Mieke Roosen
- Princess Máxima Center for pediatric oncology , Utrecht , Netherlands
| | - Phylicia Stathi
- Princess Máxima Center for pediatric oncology , Utrecht , Netherlands
| | - Aniello Federico
- Hopp Children’s Cancer Center (KiTZ) , Heidelberg , Germany
- German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | - Norman Mack
- Hopp Children’s Cancer Center (KiTZ) , Heidelberg , Germany
- German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | - Benjamin Schwalm
- Hopp Children’s Cancer Center (KiTZ) , Heidelberg , Germany
- German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | - Jens Bunt
- Princess Máxima Center for pediatric oncology , Utrecht , Netherlands
| | - Marcel Kool
- Princess Máxima Center for pediatric oncology , Utrecht , Netherlands
- Hopp Children’s Cancer Center (KiTZ) , Heidelberg , Germany
| |
Collapse
|
17
|
Hasselblatt M, Thomas C, Federico A, Nemes K, Johann PD, Bison B, Bens S, Kordes U, Redlich A, Lessel L, Pajtler KW, Mawrin C, Schüller U, Nolte K, Kramm CM, Hinz F, Sahm F, Giannini C, Penkert J, Kratz CP, Pfister SM, Siebert R, Paulus W, Kool M, Frühwald MC. ATRT-08. SMARCB1- and SMARCA4-deficient malignant brain tumors with complex copy number alterations and TP53 mutations may represent the first clinical manifestation of Li-Fraumeni syndrome. Neuro Oncol 2022. [PMCID: PMC9164743 DOI: 10.1093/neuonc/noac079.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Atypical teratoid/rhabdoid tumor (AT/RT) is a malignant central nervous system tumor predominantly affecting infants. Mutations of SMARCB1 or (rarely) SMARCA4 causing loss of nuclear SMARCB1 or SMARCA4 protein expression are characteristic features, but further recurrent genetic alterations are lacking. Most AT/RTs occur de novo, but secondary AT/RTs arising in other central nervous system tumors have been reported. Malignant gliomas, IDH-wildtype, arising in patients with Li-Fraumeni syndrome typically show somatic mutations of TP53 as well as complex copy number alterations, but little is known about loss of SMARCB1 or SMARCA4 protein expression in this context. Here we report two children, in whom malignant supratentorial brain tumors with SMARCB1-deficiency, complex copy number alterations and somatic TP53 mutations lead to the discovery of pathogenic/likely pathogenic TP53 variants in the germ line. Screening of the molecularneuropathology.org data set for cases with similar genetic and epigenetic alterations yielded another case with SMARCA4-deficiency in a young adult with Li-Fraumeni syndrome. In conclusion, SMARCB1- or SMARCA4-deficient malignant brain tumors with complex copy number alterations and somatic TP53 mutations in children and young adults may represent the first clinical manifestation of Li-Fraumeni syndrome and should prompt genetic counseling and investigation for TP53 germline status.
Collapse
Affiliation(s)
- Martin Hasselblatt
- Institute of Neuropathology, University Hospital Münster , Münster , Germany
| | - Christian Thomas
- Institute of Neuropathology, University Hospital Münster , Münster , Germany
| | - Aniello Federico
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Karolina Nemes
- Swabian Childrens' Cancer Center, University Hospital Augsburg and EU-RHAB Registry , Augsburg , Germany
| | - Pascal D Johann
- Swabian Childrens' Cancer Center, University Hospital Augsburg and EU-RHAB Registry , Augsburg , Germany
| | - Brigitte Bison
- Diagnostic and Interventional Neuroradiology, University Hospital Augsburg , Augsburg , Germany
| | - Susanne Bens
- Institute of Human Genetics, Ulm University and Ulm University Medical Center , Ulm , Germany
| | - Uwe Kordes
- Dept. of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Antje Redlich
- Department of Pediatric Oncology, Otto von Guericke University Children's Hospital , Magdeburg , Germany
| | - Lienhard Lessel
- Department of Pediatric Oncology, Otto von Guericke University Children's Hospital , Magdeburg , Germany
| | - Kristian W Pajtler
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Christian Mawrin
- Department of Neuropathology, Otto von Guericke University Magdeburg , Magdeburg , Germany
| | - Ulrich Schüller
- Dept. of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, and Research Institute Children’s Cancer Center Hamburg , Hamburg , Germany
| | - Kay Nolte
- Institute of Neuropathology, RWTH Aachen University Hospital , Aachen , Germany
| | - Christof M Kramm
- Division of Pediatric Hematology and Oncology, University Medical Center Göttingen , Göttingen , Germany
| | - Felix Hinz
- Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg , Heidelberg , Germany
| | - Felix Sahm
- Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg , Heidelberg , Germany
| | - Caterina Giannini
- Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN , USA
| | - Judith Penkert
- Pediatric Hematology and Oncology, Hannover Medical School , Hannover , Germany
| | - Christian P Kratz
- Pediatric Hematology and Oncology, Hannover Medical School , Hannover , Germany
| | - Stefan M Pfister
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Reiner Siebert
- Institute of Human Genetics, Ulm University and Ulm University Medical Center , Ulm , Germany
| | - Werner Paulus
- Institute of Neuropathology, University Hospital Münster , Münster , Germany
| | - Marcel Kool
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Princess Máxima Center for Pediatric Oncology , Utrecht , Netherlands
| | - Michael C Frühwald
- Swabian Childrens' Cancer Center, University Hospital Augsburg and EU-RHAB Registry , Augsburg , Germany
| |
Collapse
|
18
|
Kool M, Federico A, Surdez D, Gopisetty A, Saberi-Ansari E, Saint-Charles A, Iddir Y, Waterfall J, Wierzbinska J, Schlicker A, Bhalsankar J, Mack N, Schwalm B, Böttcher AL, Sill M, Westermann F, Jones DTW, Volckmann R, Zwijnenburg D, Gürgen D, Inderise E, Schulte J, Eggert A, Molenaar JJ, Delattre O, Colombetti S, Heidenreich O, Jeremias I, Scotlandi K, Manara MC, Gojo J, Berger W, Iradier F, Geoerger B, Costa J, Schäfer B, Wachtel M, Chesler L, Jones C, Kovar H, Carcaboso ÁM, Klusmann JH, Debatin KM, Bomken S, Guttke C, Hamerlik P, Hattersley M, Garcia M, Colland F, Strougo A, Witt O, Vassal G, Caron H, Shields DJ, Stancato LF, Aviles PM, Hoffmann J, Cairo S, Schueler J, Jäger N, Koster J, Schleiermacher G, Pfister SM. INSP-15. ITCC-P4: A sustainable platform of molecularly well-characterized PDX models of pediatric cancers for high throughput in vivo testing. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac079.711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Thanks to state-of-the-art molecular profiling techniques we by now have a much better understanding of pediatric cancers and what is driving them. On the other hand, we have also realized that pediatric cancers are much more heterogeneous than previously thought. Many new types and subtypes of pediatric cancers have been identified with distinct molecular and clinical characteristics. However, for many if not most of these new types and subtypes there is no specific treatment available, yet. In order to develop specific treatment protocols and to increase survival rates for pediatric cancer patients further, both at diagnosis and relapse/metastasis, we need a large collection of well-characterized preclinical models representing all the different types and subtypes. These models can be used for preclinical drug testing to prioritize the pediatric development of anticancer drugs that would be best targeting pediatric tumor biology. The ITCC-P4 consortium, which is a collaboration between many academic centers across Europe, several companies involved in in vivo preclinical testing, and ten pharmaceutical companies, started in 2017 with the overall aim to establish a sustainable platform of >400 molecularly well-characterized PDX models of high-risk pediatric cancers and to use them for in vivo testing of novel mechanism-of-action based treatments. Currently, 340 models have been fully established, including 87 brain tumor models and 253 non-brain tumor models, together representing many different tumor types both from primary and relapsed/metastatic disease. Out of these 340 models, 252 have been fully molecularly characterized, most of them together with their matching original tumors, and almost of all these models are currently being subjected to in vivo testing using three standard of care drugs and six novel mechanism-of-action based drugs. In this presentation, an update on the current status of the ITCC-P4 platform and the data we collectively have generated thus far will be presented.
Collapse
Affiliation(s)
- Marcel Kool
- Princess Máxima Center for Pediatric Oncology , Utrecht , Netherlands
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Aniello Federico
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Didier Surdez
- INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre , Paris , France
| | - Apurva Gopisetty
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Elnaz Saberi-Ansari
- INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre , Paris , France
| | - Alexandra Saint-Charles
- INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre , Paris , France
| | - Yasmine Iddir
- INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre , Paris , France
| | - Joshua Waterfall
- INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre , Paris , France
| | | | - Andreas Schlicker
- Bayer AG, Pharmaceuticals, Research and Development , Berlin , Germany
| | - Jaydutt Bhalsankar
- INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre , Paris , France
| | - Norman Mack
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Benjamin Schwalm
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Anna-Lisa Böttcher
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Martin Sill
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Frank Westermann
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - David T W Jones
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Richard Volckmann
- Department of Oncogenomics, Amsterdam University Medical Centre , Amsterdam , Netherlands
| | - Danny Zwijnenburg
- Department of Oncogenomics, Amsterdam University Medical Centre , Amsterdam , Netherlands
| | - Dennis Gürgen
- Experimental Pharmacology and Oncology Berlin-Buch GmbH , Berlin , Germany
| | | | - Johannes Schulte
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin , Berlin , Germany
| | - Angelika Eggert
- Department of Oncogenomics, Amsterdam University Medical Centre , Berlin , Germany
| | - Jan J Molenaar
- Princess Máxima Center for Pediatric Oncology , Utrecht , Netherlands
| | - Olivier Delattre
- INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre , Paris , France
| | | | - Olaf Heidenreich
- Princess Máxima Center for Pediatric Oncology , Utrecht , Netherlands
- Translational and Clinical Research Institute, Newcastle University and The Great North Children's Hospital, Newcastle upon Tyne, United Kingdom
| | - Irmela Jeremias
- Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Center for Environmental Health (HMGU), Munich, Germany; Department of Pediatrics, Dr. von Hauner Childrens Hospital, Ludwig Maximilian University of Munich (LMU) , Munich , Germany
- German Consortium for Translational Cancer Research (DKTK), Partnering Site Munich , Munich , Germany
| | - Katia Scotlandi
- IRCCS—Istituto Ortopedico Rizzoli, Experimental Oncology Laboratory , Bologna , Italy
| | - Maria Cristina Manara
- IRCCS—Istituto Ortopedico Rizzoli, Experimental Oncology Laboratory , Bologna , Italy
| | - Johannes Gojo
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
- Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna , Vienna , Austria
| | - Walter Berger
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin , Vienna , Austria
| | | | - Birgit Geoerger
- Department of Clinical Research, Gustave Roussy , Villejuif , France
| | - Jenny Costa
- Department of Clinical Research, Gustave Roussy , Villejuif , France
| | - Beat Schäfer
- University Children’s Hospital, Department of Oncology and Children’s Research Center , Zurich , Switzerland
| | - Marco Wachtel
- University Children’s Hospital, Department of Oncology and Children’s Research Center , Zurich , Switzerland
| | - Louis Chesler
- Division of Clinical Studies, The Institute of Cancer Research , London , United Kingdom
| | - Chris Jones
- Division of Molecular Pathology, Institute of Cancer Research , London , United Kingdom
| | - Heinrich Kovar
- Children's Cancer Research Institute, St Anna Kinderkrebsforschung , Vienna , Austria
| | | | - Jan-Henning Klusmann
- Department of Pediatrics I, Martin-Luther-University Halle-Wittenberg , Halle , Germany
| | - Klaus-Michael Debatin
- Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center , Ulm , Germany
| | - Simon Bomken
- Translational and Clinical Research Institute, Newcastle University and The Great North Children's Hospital, Newcastle upon Tyne, United Kingdom
| | - Christina Guttke
- Janssen Research & Development, LLC, Spring House , Pennsylvania , USA
| | | | | | | | | | - Ashley Strougo
- Sanofi-Aventis Deutschland GmbH, R&D , Frankfurt , Germany
| | - Olaf Witt
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Gilles Vassal
- Department of Clinical Research, Gustave Roussy , Villejuif , France
- European consortium for Innovative Therapies for Children with Cancer (ITCC) , Paris , France
| | | | - David J Shields
- Pfizer Centers for Therapeutic Innovation, Pfizer Inc , New York , USA
| | | | - Pablo M Aviles
- Institut de Recerca Sant Joan de Deu , Barcelona , Spain
| | - Jens Hoffmann
- Experimental Pharmacology and Oncology Berlin-Buch GmbH , Berlin , Germany
| | | | - Julia Schueler
- Charles River Discovery Research Services Germany , Freiburg , Germany
| | - Natalie Jäger
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Jan Koster
- Department of Oncogenomics, Amsterdam University Medical Centre , Amsterdam , Netherlands
| | - Gudrun Schleiermacher
- INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre , Paris , France
| | - Stefan M Pfister
- Hopp Children’s Cancer Center , Heidelberg , Germany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| |
Collapse
|
19
|
Blanco-Carmona E, Büllesbach A, Federico A, Liu I, Young MD, Kildisuite G, Behjati S, Vibhakar R, Donson A, Foreman N, Hovestadt V, Shaw M, Chi S, Frühwald M, Drost J, Korshunov A, Hasselblatt M, Pfister SM, Jäger N, Johann P, Filbin M, Kool M. ATRT-10. Single-cell transcriptional profiling of ATRTs reveals heterogeneous signatures of tumor and non-malignant cell populations. Neuro Oncol 2022. [PMCID: PMC9164679 DOI: 10.1093/neuonc/noac079.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Atypical Teratoid/Rhabdoid Tumors (ATRTs) are known for exhibiting high inter-tumor heterogeneity, even though they are almost all characterized by a common loss of SMARCB1 (or rarely SMARCA4). Three subgroups have been identified at bulk methylome and transcriptome level: ATRT-TYR, ATRT-SHH, and ATRT-MYC. To better understand the biology underlying each subgroup and potentially unveil their (different) cell(s) of origin, we performed single-cell transcriptomic analyses in 22 ATRTs using fresh frozen samples and both 10X and Smartseq technology. All data, grouped by technology, underwent quality control and normalization, regressing out the biases introduced by each sample. Tumor microenvironment (TME) and tumor bulk (TB) clusters were characterized by a combination of copy number variant analyses, enrichment in literature lists of marker genes for specific cell populations, and in-depth analysis of differentially enriched (DE) genes. Non-negative Matrix Factorization (NMF) was applied to TB to reveal major transcriptional profiles, which were grouped into meta-signatures. A total of 71 gene lists were retrieved from NMF (TB) and DE analyses (TME + TB), that gathered into 11 signature groups by Jaccard similarity, with one extra group accounting for unique signatures. Three groups targeted TME, accounting for either microglia, fibroblasts and endothelial cells, or OPCs, oligodendrocytes, astrocytes and neurons. These signatures are enriched in specific clusters across technologies. The remaining eight groups divide into two types, either enriched in clusters predominantly formed by cells of one or two ATRT subgroups or signatures enriched for a particular phenotype, such as cilial, cycling, axonogenesis or EM transition. While the first type is enriched across clusters in a gradient fashion, the second shows enrichment for selected clusters across technologies. Further analyses on the integrated dataset and additional samples are ongoing to validate and refine these 11 signature groups in ATRTs to see how this may lead to new treatment approaches.
Collapse
Affiliation(s)
- Enrique Blanco-Carmona
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Annette Büllesbach
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Aniello Federico
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Ilon Liu
- Broad Institute of Harvard and MIT , Cambridge , USA
| | | | | | - Sam Behjati
- Wellcome Sanger Institute , Hinxton , United Kingdom
- Department of Paediatrics , Cambridge , United Kingdom
| | - Rajeev Vibhakar
- Morgan Adams Foundation Pediatric Brain Tumor Research Program , Aurora , USA
- Children’s Hospital Colorado , Aurora , USA
| | - Andrew Donson
- Morgan Adams Foundation Pediatric Brain Tumor Research Program , Aurora , USA
- Children’s Hospital Colorado , Aurora , USA
| | - Nicholas Foreman
- Morgan Adams Foundation Pediatric Brain Tumor Research Program , Aurora , USA
- Children’s Hospital Colorado , Aurora , USA
| | - Volker Hovestadt
- Broad Institute of Harvard and MIT , Cambridge , USA
- Department of Pediatric Oncology, Dana-Farber Boston Children’s Cancer and Blood Disorders Center , Boston , USA
| | - McKenzie Shaw
- Broad Institute of Harvard and MIT , Cambridge , USA
| | - Susan Chi
- Broad Institute of Harvard and MIT , Cambridge , USA
| | - Michael Frühwald
- Swabian Children’s Cancer Center, University Hospital of Augsburg , Augsburg , Germany
| | - Jarno Drost
- Princess Máxima Center for Pediatric Oncology , Utrecht , Netherlands
- Oncode Institute , Utrecht , Netherlands
| | - Andrey Korshunov
- Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital , Heidelberg , Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) , Heidelberg , Germany
| | - Martin Hasselblatt
- Institute of Neuropathology, University Hospital Münster , Münster , Germany
| | - Stefan M Pfister
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Natalie Jäger
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) , Heidelberg , Germany
| | - Pascal Johann
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Swabian Children’s Cancer Center, University Hospital of Augsburg , Augsburg , Germany
| | - Mariella Filbin
- Broad Institute of Harvard and MIT , Cambridge , USA
- Department of Pediatric Oncology, Dana-Farber Boston Children’s Cancer and Blood Disorders Center , Boston , USA
| | - Marcel Kool
- Hopp Children's Cancer Center (KiTZ) , Heidelberg , Germany
- Princess Máxima Center for Pediatric Oncology , Utrecht , Netherlands
| |
Collapse
|
20
|
Federico A, Anchora LP, Scambia G, Ferrandina G. ASO Author Reflections: Role of Adjuvant Surgery in Locally Advanced Cervical Cancer: An Unresolved Issue. Ann Surg Oncol 2022; 29:4815-4816. [DOI: 10.1245/s10434-022-11620-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Accepted: 03/04/2022] [Indexed: 11/18/2022]
|
21
|
Hasselblatt M, Thomas C, Federico A, Bens S, Hellström M, Casar‐Borota O, Kordes U, Neumann JE, Dottermusch M, Rodriguez FJ, Lo AC, Cheng S, Hendson G, Hukin J, Hartmann C, Koch A, Capper D, Siebert R, Paulus W, Nemes K, Johann PD, Frühwald MC, Kool M. Low‐grade diffusely infiltrative tumour (LGDIT), SMARCB1‐mutant: a clinical and histopathological distinct entity showing epigenetic similarity with ATRT‐MYC. Neuropathol Appl Neurobiol 2022; 48:e12797. [DOI: 10.1111/nan.12797] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 01/03/2022] [Accepted: 02/05/2022] [Indexed: 11/30/2022]
Affiliation(s)
| | - Christian Thomas
- Institute of Neuropathology University Hospital Münster Münster Germany
| | - Aniello Federico
- Hopp Children´s Cancer Center (KiTZ), Heidelberg Germany
- Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg Germany
| | - Susanne Bens
- Institute of Human Genetics Ulm University & Ulm University Medical Center Ulm Germany
| | - Mats Hellström
- Dept. of Immunology, Genetics and Pathology, Rudbeck Laboratory Uppsala University Uppsala Sweden
| | - Olivera Casar‐Borota
- Dept. of Immunology, Genetics and Pathology, Rudbeck Laboratory Uppsala University Uppsala Sweden
- Dept. of Clinical Pathology Uppsala University Hospital Uppsala Sweden
| | - Uwe Kordes
- Dept. of Pediatric Hematology and Oncology University Medical Center, Hamburg‐Eppendorf Hamburg Germany
| | - Julia E. Neumann
- Institute of Neuropathology, University Medical Center, Hamburg‐Eppendorf Hamburg Germany
- Center for Molecular Neurobiology Hamburg (ZMNH) University Medical Center Hamburg‐Eppendorf Hamburg Germany
| | - Matthias Dottermusch
- Institute of Neuropathology, University Medical Center, Hamburg‐Eppendorf Hamburg Germany
- Center for Molecular Neurobiology Hamburg (ZMNH) University Medical Center Hamburg‐Eppendorf Hamburg Germany
| | - Fausto J. Rodriguez
- Dept. of Pathology The Johns Hopkins University School of Medicine Baltimore MD USA
| | - Andrea C. Lo
- Radiation Oncology British Columbia Cancer and University of British Columbia Vancouver Canada
| | - Sylvia Cheng
- Division of Hematology, Oncology & BMT, Department of Pediatrics University of British Columbia Vancouver Canada
| | - Glenda Hendson
- Dept. of Pathology, BC Women and Children's Hospital Vancouver Canada
| | - Juliette Hukin
- Division of Hematology, Oncology & BMT, Department of Pediatrics University of British Columbia Vancouver Canada
| | - Christian Hartmann
- Dept. of Neuropathology Institute of Pathology, Hannover Medical School Hannover Germany
| | - Arend Koch
- Charité ‐ Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin, Dept. of Neuropathology Berlin Germany
| | - David Capper
- Charité ‐ Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin, Dept. of Neuropathology Berlin Germany
- German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg Germany
| | - Reiner Siebert
- Institute of Human Genetics Ulm University & Ulm University Medical Center Ulm Germany
| | - Werner Paulus
- Institute of Neuropathology University Hospital Münster Münster Germany
| | - Karolina Nemes
- Pediatric and Adolescent Medicine, Swabian Childrens' Cancer Center University Childrens' Hospital Medical Center Augsburg and EU‐RHAB Registry Augsburg Germany
| | - Pascal D. Johann
- Hopp Children´s Cancer Center (KiTZ), Heidelberg Germany
- Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg Germany
- Pediatric and Adolescent Medicine, Swabian Childrens' Cancer Center University Childrens' Hospital Medical Center Augsburg and EU‐RHAB Registry Augsburg Germany
| | - Michael C. Frühwald
- Pediatric and Adolescent Medicine, Swabian Childrens' Cancer Center University Childrens' Hospital Medical Center Augsburg and EU‐RHAB Registry Augsburg Germany
| | - Marcel Kool
- Hopp Children´s Cancer Center (KiTZ), Heidelberg Germany
- Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg Germany
- Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands
| |
Collapse
|
22
|
Whitehouse JP, Howlett M, Federico A, Kool M, Endersby R, Gottardo NG. Defining the molecular features of radiation-induced glioma: A systematic review and meta-analysis. Neurooncol Adv 2021; 3:vdab109. [PMID: 34859225 PMCID: PMC8633655 DOI: 10.1093/noajnl/vdab109] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Background Cranial radiation therapy is essential in treating many pediatric cancers, especially brain tumors; however, its use comes with the risk of developing second malignancies. Cranial radiation-induced gliomas (RIGs) are aggressive high-grade tumors with a dismal prognosis, for which no standard therapy exists. A definitive molecular signature for RIGs has not yet been established. We sought to address this gap by performing a systematic review and meta-analysis of the molecular features of cranial RIGs. Methods A systematic review of the literature was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Articles and case reports that described molecular analyses of cranial radiation-induced high-grade gliomas were identified and evaluated, and data extracted for collation. Results Of 1727 records identified, 31 were eligible, containing 102 unique RIGs with molecular data. The most frequent genetic alterations in RIGs included PDGFRA or TP53 mutations, PDGFRA or CDK4 amplifications, and CDKN2A deletion, along with 1q gain, 1p loss and 13q loss. Of note, mutations in ACVR1, EGFR, H3F3A, HIST1H3B, HIST1H3C, IDH2, SMARCB1 or the TERT promoter were not observed. A comparative analysis revealed that RIGs are molecularly distinct from most other astrocytomas and gliomas and instead align most closely with the pedGBM_RTK1 subgroup of pediatric glioblastoma. Conclusions This comprehensive analysis highlights the major molecular features of RIGs, demonstrates their molecular distinction from many other astrocytomas and gliomas, and reveals potential genetic drivers and therapeutic targets for this currently fatal disease.
Collapse
Affiliation(s)
- Jacqueline P Whitehouse
- Brain Tumour Research Program, Telethon Kids Institute, Nedlands, Western Australia, Australia.,Centre for Child Health Research, University of Western Australia, Nedlands, Western Australia, Australia
| | - Meegan Howlett
- Brain Tumour Research Program, Telethon Kids Institute, Nedlands, Western Australia, Australia.,Centre for Child Health Research, University of Western Australia, Nedlands, Western Australia, Australia
| | - Aniello Federico
- Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.,Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Marcel Kool
- Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.,Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.,Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
| | - Raelene Endersby
- Brain Tumour Research Program, Telethon Kids Institute, Nedlands, Western Australia, Australia.,Centre for Child Health Research, University of Western Australia, Nedlands, Western Australia, Australia
| | - Nicholas G Gottardo
- Brain Tumour Research Program, Telethon Kids Institute, Nedlands, Western Australia, Australia.,Centre for Child Health Research, University of Western Australia, Nedlands, Western Australia, Australia.,Department of Paediatric and Adolescent Oncology/Haematology, Perth Children's Hospital, Nedlands, Western Australia, Australia
| |
Collapse
|
23
|
Federico A, Kool M. OTME-3. Dissection of the role of stromal microenvironment and tumor-TME crosstalk in pediatric brain cancer. Neurooncol Adv 2021. [PMCID: PMC8255459 DOI: 10.1093/noajnl/vdab070.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Brain tumors are the deadliest malignancies that occur during childhood and strong efforts are required to develop innovative therapeutic strategies. The intrinsic capacity of malignant cells to organize, shape and exploit the surrounding environment where they develop (tumor microenvironment, TME), has not been fully elucidated for pediatric brain cancers yet. Here, we exploited a multi-omic approach to define the TME cell populations and their contributions in the most common pediatric brain tumor entities, such as medulloblastomas and ependymomas. Analysis of single-cell RNA sequencing data of human tumors resulted in the identification of heterogeneous populations of non-malignant cells present in the TME. In particular, re-clustering and marker-based cell type assignment strategies allowed to define a broad range of immune and stromal subclasses showing distinctive expression signatures reflecting variegated functional roles. By cross-matching the tumor data with normal brain expression atlases, we could further refine the annotation of the newly identified stromal functional subpopulations and define the “tumor-associated” marker signatures of genes exclusively enriched in stromal cells within the TME, linked to immune activation, cell adhesion and cytokine regulation pathways. Bulk transcriptomic data of human tumors and matching patient-derived xenografts (PDXs) showed that a group of secreted stromal factors acting as regulators of tumorigenic mechanisms, such as IGF2 and COL4A1, are lost after xenografting and replaced by the host murine microenvironment, suggesting that tumor cells are involved in paracrine and bivalent crosstalk with TME cells, impacting on tumor cell growth and progression. Finally, bulk deconvolution and cell-cell communication analysis were exploited to define, respectively, the stromal cell proportions and the key factors involved in the tumor-TME crosstalk; this latter can be considered as possible targets for tailored and more specific anti-tumor therapeutic strategies.
Collapse
Affiliation(s)
- Aniello Federico
- Hopp-Children’s Cancer Center (KiTZ), Heidelberg, Germany
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Marcel Kool
- Hopp-Children’s Cancer Center (KiTZ), Heidelberg, Germany
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
| |
Collapse
|
24
|
Sun Q, Novak D, Hüser L, Poelchen J, Wu H, Granados K, Federico A, Liu K, Steinfass T, Vierthaler M, Umansky V, Utikal J. FOXD1 promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factor. Int J Cancer 2021; 149:657-674. [PMID: 33837564 DOI: 10.1002/ijc.33591] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 03/22/2021] [Accepted: 03/26/2021] [Indexed: 12/11/2022]
Abstract
Metastatic melanoma is an aggressive skin cancer and associated with a poor prognosis. In clinical terms, targeted therapy is one of the most important treatments for patients with BRAFV600E -mutated advanced melanoma. However, the development of resistance to this treatment compromises its therapeutic success. We previously demonstrated that forkhead box D1 (FOXD1) regulates melanoma migration and invasion. Here, we found that FOXD1 was highly expressed in melanoma cells and was associated with a poor survival of patients with metastatic melanoma. Upregulation of FOXD1 expression enhanced melanoma cells' resistance to vemurafenib (BRAF inhibitor [BRAFi]) or vemurafenib and cobimetinib (MEK inhibitor) combination treatment whereas loss of FOXD1 increased the sensitivity to treatment. By comparing gene expression levels between FOXD1 knockdown (KD) and overexpressing (OE) cells, we identified the connective tissue growth factor (CTGF) as a downstream factor of FOXD1. Chromatin immunoprecipitation and luciferase assay demonstrated the direct binding of FOXD1 to the CTGF promoter. Similar to FOXD1, knockdown of CTGF increased the sensitivity of BRAFi-resistant cells to vemurafenib. FOXD1 KD cells treated with recombinant CTGF protein were less sensitive towards vemurafenib compared to untreated FOXD1 KD cells. Based on these findings, we conclude that FOXD1 might be a promising new diagnostic marker and a therapeutic target for the treatment of targeted therapy resistant melanoma.
Collapse
Affiliation(s)
- Qian Sun
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany
| | - Daniel Novak
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany
| | - Laura Hüser
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany
| | - Juliane Poelchen
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany
| | - Huizi Wu
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany.,BGI Genomics, Beijing Genomics Institute, Shenzhen, China
| | - Karol Granados
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany.,Department of Biochemistry, School of Medicine, University of Costa Rica (UCR), San Jose, Costa Rica
| | - Aniello Federico
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany
| | - Ke Liu
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany.,Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Tamara Steinfass
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany
| | - Marlene Vierthaler
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany
| | - Viktor Umansky
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany
| | - Jochen Utikal
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany
| |
Collapse
|
25
|
Gravina AG, Tessitore A, Ormando VM, Nagar F, Romeo M, Amato MR, Dallio M, Loguercio C, Federico A, Romano M, Ferraro F. May chronic cough in chronic obstructive pulmonary disease be a contraindication of Percutaneous Endoscopic Gastrostomy placement: a case report. BMC Gastroenterol 2021; 21:31. [PMID: 33478385 PMCID: PMC7819233 DOI: 10.1186/s12876-021-01603-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2020] [Accepted: 01/06/2021] [Indexed: 11/13/2022] Open
Abstract
Background Percutaneous Endoscopic Gastrostomy (PEG) can involve some complications, despite the good safety of its track record. The Buried Bumper Syndrome (BBS) is a rare, late and dangerous complication that consists in the erosion of the internal bumper through the gastric wall. Case presentation We report the development of BBS in a man with chronic obstructive pulmonary disease (COPD) who had a persistent chronic cough which was prevalently but not solely in the morning and required placement of a PEG tube for continuous infusion of Levodopa/carbidopa intestinal gel for advanced Parkinson's disease. Conclusion We believe that COPD with chronic cough while not representing an absolute contraindication to PEG placement, may potentially cause BBS and therefore an appropriate regimen of tube care by expert personnel is mandatory in this setting.
Collapse
Affiliation(s)
- A G Gravina
- Hepatogastropenterology Unit, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via Pansini, 5, 80131, Naples, Italy.
| | - A Tessitore
- Department of Medical, Surgical, Neurological, Metabolic and Geriatric Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - V M Ormando
- Hepatogastropenterology Unit, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via Pansini, 5, 80131, Naples, Italy
| | - F Nagar
- Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - M Romeo
- Hepatogastropenterology Unit, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via Pansini, 5, 80131, Naples, Italy
| | - M R Amato
- Hepatogastropenterology Unit, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via Pansini, 5, 80131, Naples, Italy
| | - M Dallio
- Hepatogastropenterology Unit, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via Pansini, 5, 80131, Naples, Italy
| | - C Loguercio
- Hepatogastropenterology Unit, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via Pansini, 5, 80131, Naples, Italy
| | - A Federico
- Hepatogastropenterology Unit, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via Pansini, 5, 80131, Naples, Italy
| | - M Romano
- Hepatogastropenterology Unit, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via Pansini, 5, 80131, Naples, Italy
| | - F Ferraro
- Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy
| |
Collapse
|
26
|
Ferrandina G, Gallotta V, Federico A, Fanfani F, Ercoli A, Chiantera V, Cosentino F, Turco LC, Legge F, Anchora LP, Bizzarri N, Moroni R, Macchia G, Valentini V, Scambia G. Minimally Invasive Approaches in Locally Advanced Cervical Cancer Patients Undergoing Radical Surgery After Chemoradiotherapy: A Propensity Score Analysis. Ann Surg Oncol 2020; 28:3616-3626. [PMID: 33165720 PMCID: PMC8184543 DOI: 10.1245/s10434-020-09302-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Accepted: 10/13/2020] [Indexed: 12/24/2022]
Abstract
Purpose Chemoradiation (CT/RT) followed by radical surgery (RS) may play a role in locally advanced cervical cancer (LACC) patients with suboptimal response to CT/RT or in low-income countries with limited access to radiotherapy. Our aim is to evaluate oncological and surgical outcomes of minimally invasive radical surgery (MI-RS) compared with open radical surgery (O-RS). Patients and Methods Data for stage IB2–IVA cervical cancer patients managed by CT/RT and RS were retrospectively analyzed. Results Beginning with 686 patients, propensity score matching resulted in 462 cases (231 per group), balanced for FIGO stage, lymph node status, histotype, tumor grade, and clinical response to CT/RT. The 5-year disease-free survival (DFS) was 73.7% in the O-RS patients and 73.0% in the MI-RS patients (HR 1.034, 95% CI 0.708–1.512, p = 0.861). The 5-year locoregional recurrence rate was 12.5% (O-RS) versus 15.2% (MI-RS) (HR 1.174, 95% CI 0.656–2.104, p = 0.588). The 5-year disease-specific survival (DSS) was 80.4% in O-RS patients and 85.3% in the MI-RS group (HR 0.731, 95% CI 0.438–1.220, p = 0.228). Estimated blood loss was lower in the MI-RS group (p < 0.001), as was length of hospital stay (p < 0.001). Early postoperative complications occurred in 77 patients (33.3%) in the O-RS group versus 88 patients (38.1%) in the MI-RS group (p = 0.331). Fifty-six (24.2%) patients experienced late postoperative complications in the O-RS group, versus 61 patients (26.4%) in the MI-RS group (p = 0.668). Conclusion MI-RS and O-RS are associated with similar rates of recurrence and death in LACC patients managed by surgery after CT/RT. No difference in early or late complications was reported. Electronic supplementary material The online version of this article (10.1245/s10434-020-09302-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- G Ferrandina
- Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.,Istituto di Ginecologia e Ostetricia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - V Gallotta
- Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
| | - A Federico
- Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
| | - F Fanfani
- Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.,Istituto di Ginecologia e Ostetricia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - A Ercoli
- Department of Obstetrics and Gynecology, University of Messina, Messina, Italy
| | - V Chiantera
- Department of Gynecologic Oncology, University of Palermo, Palermo, Italy
| | - F Cosentino
- Gynecologic Oncology, Gemelli Molise, Campobasso, Italy
| | - L C Turco
- Gynecology and Breast Care Unit, Mater Olbia Hospital, Olbia, Italy
| | - F Legge
- Gynecologic Oncology Unit, Department Obstetrics/Gynecology "F. Miulli" General Regional Hospital, Acquaviva delle Fonti, Bari, Italy
| | - L Pedone Anchora
- Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
| | - N Bizzarri
- Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
| | - R Moroni
- Direzione Scientifica, Fondazione Policlinico Universitario A.Gemelli, IRCCS, Rome, Italy
| | - G Macchia
- Radiotherapy Unit, Gemelli Molise Hospital, Campobasso, Italy
| | - V Valentini
- Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC di Radioterapia, Rome, Italy.,Istituto di Radiologia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - G Scambia
- Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.,Istituto di Ginecologia e Ostetricia, Università Cattolica del Sacro Cuore, Rome, Italy
| |
Collapse
|
27
|
Bersano A, Kraemer M, Burlina A, Mancuso M, Finsterer J, Sacco S, Salvarani C, Caputi L, Chabriat H, Oberstein SL, Federico A, Tournier-Lasserve E, Hunt D, Dichgans M, Arnold M, Debette S, Markus HS. Correction to: Heritable and non-heritable uncommon causes of stroke. J Neurol 2020; 268:2808-2809. [PMID: 32556534 DOI: 10.1007/s00415-020-09948-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- A Bersano
- Cerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
| | - M Kraemer
- Department of Neurology Alfried, Krupp-Hospital, Essen, Germany.,Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany
| | - A Burlina
- Neurological Unit, St. Bassano Hospital, Bassano del Grappa, Italy
| | - M Mancuso
- Department of Clinical and Experimental Medicine, Neurological Institute, University of Pisa, Pisa, Italy
| | - J Finsterer
- Krankenanstalt Rudolfstiftung, Messerli Institute, Vienna, Austria
| | - S Sacco
- Department of Neurology, Avezzano Hospital, University of L'Aquila, L'Aquila, Italy
| | - C Salvarani
- University of Modena and Reggio Emilia, and Azienda USL-IRCCS, Reggio Emilia, Italy
| | - L Caputi
- Cerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - H Chabriat
- Department of Neurology and CERVCO, DHU Neurovasc, INSERM U1141, University of Paris, Paris, France
| | - S Lesnik Oberstein
- Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - A Federico
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - E Tournier-Lasserve
- Department of Genetics, Lariboisière Hospital and INSERM U1141, Paris-Diderot University, Paris, France
| | - D Hunt
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK
| | - M Dichgans
- Institute for Stroke and Dementia Research, Klinikum Der Universität München, Munich, Germany
| | - M Arnold
- Inserm Centre Bordeaux Population Health (U1219), University of Bordeaux, Bordeaux, France
| | - S Debette
- Department of Neurology, INSELSPITAL, University Hospital Bern, Bern, Switzerland
| | - H S Markus
- Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| |
Collapse
|
28
|
Federico A, Steinfass T, Larribère L, Novak D, Morís F, Núñez LE, Umansky V, Utikal J. Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma. Mol Ther Oncolytics 2020; 18:83-99. [PMID: 32637583 PMCID: PMC7327877 DOI: 10.1016/j.omto.2020.06.001] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Accepted: 06/01/2020] [Indexed: 12/24/2022]
Abstract
Malignant melanoma is the most deadly skin cancer, associated with rising incidence and mortality rates. Most of the patients with melanoma, treated with current targeted therapies, develop a drug resistance, causing tumor relapse. The attainment of a better understanding of novel cancer-promoting molecular mechanisms driving melanoma progression is essential for the development of more effective targeted therapeutic approaches. Recent studies, including the research previously conducted in our laboratory, reported that the histone methyltransferase SETDB1 contributes to melanoma pathogenesis. In this follow-up study, we further elucidated the role of SETDB1 in melanoma, showing that SETDB1 modulated relevant transcriptomic effects in melanoma, in particular, as activator of cancer-related secreted (CRS) factors and as repressor of melanocyte-lineage differentiation (MLD) and metabolic enzymes. Next, we investigated the effects of SETDB1 inhibition via compounds belonging to the mithramycin family, mithramycin A and mithramycin analog (mithralog) EC-8042: melanoma cells showed strong sensitivity to these drugs, which effectively suppressed the expression of SETDB1 and induced changes at the transcriptomic, morphological, and functional level. Moreover, SETDB1 inhibitors enhanced the efficacy of mitogen-activated protein kinase (MAPK) inhibitor-based therapies against melanoma. Taken together, this work highlights the key regulatory role of SETDB1 in melanoma and supports the development of SETDB1-targeting therapeutic strategies for the treatment of melanoma patients.
Collapse
Affiliation(s)
- Aniello Federico
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, 69120 Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, 68135 Baden Württemberg, Germany
| | - Tamara Steinfass
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, 69120 Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, 68135 Baden Württemberg, Germany
| | - Lionel Larribère
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, 69120 Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, 68135 Baden Württemberg, Germany
| | - Daniel Novak
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, 69120 Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, 68135 Baden Württemberg, Germany
| | - Francisco Morís
- EntreChem SL, Vivero Ciencias de la Salud, 33011 Oviedo, Spain
| | - Luz-Elena Núñez
- EntreChem SL, Vivero Ciencias de la Salud, 33011 Oviedo, Spain
| | - Viktor Umansky
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, 69120 Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, 68135 Baden Württemberg, Germany
| | - Jochen Utikal
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, 69120 Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, 68135 Baden Württemberg, Germany
| |
Collapse
|
29
|
Mancuso M, Arnold M, Bersano A, Burlina A, Chabriat H, Debette S, Enzinger C, Federico A, Filla A, Finsterer J, Hunt D, Lesnik Oberstein S, Tournier-Lasserve E, Markus HS. Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology. Eur J Neurol 2020; 27:909-927. [PMID: 32196841 DOI: 10.1111/ene.14183] [Citation(s) in RCA: 91] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Accepted: 02/11/2020] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND PURPOSE Guidelines on monogenic cerebral small-vessel disease (cSVD) diagnosis and management are lacking. Endorsed by the Stroke and Neurogenetics Panels of the European Academy of Neurology, a group of experts has provided recommendations on selected monogenic cSVDs, i.e. cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), autosomal dominant High Temperature Requirement A Serine Peptidase 1 (HTRA1), cathepsin-A-related arteriopathy with strokes and leukoencephalopathy (CARASAL), pontine autosomal dominant microangiopathy and leukoencephalopathy (PADMAL), Fabry disease, mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) and type IV collagen (COL4)A1/2. METHODS We followed the Delphi methodology to provide recommendations on several unanswered questions related to monogenic cSVD, including genetic testing, clinical and neuroradiological diagnosis, and management. RESULTS We have proposed 'red-flag' features suggestive of a monogenic disease. General principles applying to the management of all cSVDs and specific recommendations for the individual forms of monogenic cSVD were agreed by consensus. CONCLUSIONS The results provide a framework for clinicians involved in the diagnosis and management of monogenic cSVD. Further multicentre observational and treatment studies are still needed to increase the level of evidence supporting our recommendations.
Collapse
Affiliation(s)
- M Mancuso
- Department of Clinical and Experimental Medicine, Neurological Institute, University of Pisa, Pisa, Italy
| | - M Arnold
- Department of Neurology, INSELSPITAL, University Hospital Bern, Bern, Switzerland
| | - A Bersano
- Cerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - A Burlina
- Neurological Unit, St. Bassiano Hospital, Bassano del Grappa, Italy
| | - H Chabriat
- Department of Neurology and CERVCO, DHU Neurovasc, INSERM U1141, University of Paris, Paris, France
| | - S Debette
- Department of Neurology, INSERM Centre Bordeaux Population Health (U1219), Bordeaux University Hospital, University of Bordeaux, Bordeaux, France
| | - C Enzinger
- Department of Neurology and Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Graz, Austria
| | - A Federico
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - A Filla
- Department of Neurosciences and Reproductive and Odontostomatological Sciences, Federico II University, Napoli, Italy
| | - J Finsterer
- Krankenanstalt Rudolfstiftung, Messerli Institute, Vienna, Austria
| | - D Hunt
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - S Lesnik Oberstein
- Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - E Tournier-Lasserve
- Department of Genetics, Lariboisière Hospital and INSERM U1141, Paris-Diderot University, Paris, France
| | - H S Markus
- Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| |
Collapse
|
30
|
Bersano A, Kraemer M, Burlina A, Mancuso M, Finsterer J, Sacco S, Salvarani C, Caputi L, Chabriat H, Oberstein SL, Federico A, Lasserve ET, Hunt D, Dichgans M, Arnold M, Debette S, Markus HS. Heritable and non-heritable uncommon causes of stroke. J Neurol 2020; 268:2780-2807. [PMID: 32318851 DOI: 10.1007/s00415-020-09836-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2019] [Revised: 04/09/2020] [Accepted: 04/10/2020] [Indexed: 12/15/2022]
Abstract
Despite intensive investigations, about 30% of stroke cases remains of undetermined origin. After exclusion of common causes of stroke, there is a number of rare heritable and non-heritable conditions, which often remain misdiagnosed, that should be additionally considered in the diagnosis of cryptogenic stroke. The identification of these diseases requires a complex work up including detailed clinical evaluation for the detection of systemic symptoms and signs, an adequate neuroimaging assessment and a careful family history collection. The task becomes more complicated by phenotype heterogeneity since stroke could be the primary or unique manifestation of a syndrome or represent just a manifestation (sometimes minor) of a multisystem disorder. The aim of this review paper is to provide clinicians with an update on clinical and neuroradiological features and a set of practical suggestions for the diagnostic work up and management of these uncommon causes of stroke. The identification of these stroke causes is important to avoid inappropriate and expensive diagnostic tests, to establish appropriate management measures, including presymptomatic testing, genetic counseling, and, if available, therapy. Therefore, physicians should become familiar with these diseases to provide future risk assessment and family counseling.
Collapse
Affiliation(s)
- A Bersano
- Cerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
| | - M Kraemer
- Department of Neurology Alfried, Krupp-Hospital, Essen, Germany.,Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany
| | - A Burlina
- Neurological Unit, St. Bassano Hospital, Bassano del Grappa, Italy
| | - M Mancuso
- Department of Clinical and Experimental Medicine, Neurological Institute, University of Pisa, Pisa, Italy
| | - J Finsterer
- Krankenanstalt Rudolfstiftung, Messerli Institute, Vienna, Austria
| | - S Sacco
- Department of Neurology, Avezzano Hospital, University of L'Aquila, L'Aquila, Italy
| | - C Salvarani
- University of Modena and Reggio Emilia, and Azienda USL-IRCCS, Reggio Emilia, Italy
| | - L Caputi
- Cerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - H Chabriat
- Department of Neurology and CERVCO, DHU Neurovasc, INSERM U1141, University of Paris, Paris, France
| | - S Lesnik Oberstein
- Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - A Federico
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - E Tournier Lasserve
- Department of Genetics, Lariboisière Hospital and INSERM U1141, Paris-Diderot University, Paris, France
| | - D Hunt
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK
| | - M Dichgans
- Institute for Stroke and Dementia Research, Klinikum Der Universität München, Munich, Germany
| | - M Arnold
- Inserm Centre Bordeaux Population Health (U1219), University of Bordeaux, Bordeaux, France
| | - S Debette
- Department of Neurology, INSELSPITAL, University Hospital Bern, Bern, Switzerland
| | - H S Markus
- Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| |
Collapse
|
31
|
Granados K, Hüser L, Federico A, Sachindra S, Wolff G, Hielscher T, Novak D, Madrigal-Gamboa V, Sun Q, Vierthaler M, Larribère L, Umansky V, Utikal J. T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells. Br J Cancer 2020; 122:1023-1036. [PMID: 32063604 PMCID: PMC7109069 DOI: 10.1038/s41416-020-0751-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2019] [Revised: 12/19/2019] [Accepted: 01/24/2020] [Indexed: 11/25/2022] Open
Abstract
Background Drug resistance remains as one of the major challenges in melanoma therapy. It is well known that tumour cells undergo phenotypic switching during melanoma progression, increasing melanoma plasticity and resistance to mitogen-activated protein kinase inhibitors (MAPKi). Methods We investigated the melanoma phenotype switching using a partial reprogramming model to de-differentiate murine melanoma cells and target melanoma therapy adaptation against MAPKi. Results Here, we show that partially reprogrammed cells are a less proliferative and more de-differentiated cell population, expressing a gene signature for stemness and suppressing melanocyte-specific markers. To investigate adaptation to MAPKi, cells were exposed to B-Raf Proto-Oncogene (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors. De-differentiated cells became less sensitive to MAPKi, showed increased cell viability and decreased apoptosis. Furthermore, T-type calcium channels expression increased in adaptive murine cells and in human adaptive melanoma cells. Treatment with the calcium channel blocker mibefradil induced cell death, differentiation and susceptibility to MAPKi in vitro and in vivo. Conclusion In summary, we show that partial reprogramming of melanoma cells induces de-differentiation and adaptation to MAPKi. Moreover, we postulated a calcium channel blocker such as mibefradil, as a potential candidate to restore sensitivity to MAPKi in adaptive melanoma cells.
Collapse
Affiliation(s)
- Karol Granados
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, D-68135, Mannheim, Germany.,Department of Biochemistry, School of Medicine, University of Costa Rica (UCR), Rodrigo Facio Campus, San Pedro Montes Oca, San Jose, 2060, Costa Rica
| | - Laura Hüser
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, D-68135, Mannheim, Germany
| | - Aniello Federico
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, D-68135, Mannheim, Germany
| | - Sachindra Sachindra
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, D-68135, Mannheim, Germany.,Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Gretchen Wolff
- Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany
| | - Thomas Hielscher
- Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Daniel Novak
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, D-68135, Mannheim, Germany
| | - Verónica Madrigal-Gamboa
- Department of Biochemistry, School of Medicine, University of Costa Rica (UCR), Rodrigo Facio Campus, San Pedro Montes Oca, San Jose, 2060, Costa Rica
| | - Qian Sun
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, D-68135, Mannheim, Germany
| | - Marlene Vierthaler
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, D-68135, Mannheim, Germany
| | - Lionel Larribère
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, D-68135, Mannheim, Germany
| | - Viktor Umansky
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, D-68135, Mannheim, Germany
| | - Jochen Utikal
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, D-68135, Mannheim, Germany.
| |
Collapse
|
32
|
Granados K, Hüser L, Federico A, Sachindra S, Wolff G, Umansky V, Utikal J. Abstract 1274: Partial reprogramming of melanoma cells confers drug resistance and increased vulnerability to channel antagonists. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-1274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
During melanoma progression, tumor cells undergo phenotypic switching, increasing melanoma plasticity and resistance to mitogen-activated protein kinase inhibitors (MAPKi). We propose a partial reprogramming model to target melanoma therapy resistance. Here we show that partially reprogrammed cells are a less proliferative and more dedifferentiated cell population, expressing a gene signature for stemness and suppressing melanocyte-specific markers. To investigate the development of resistance to MAPKi, cells were exposed to BRAF and MEK inhibitors. Partially reprogrammed cells become less sensitive to MAPKi, showing increased cell viability and decreased apoptosis. Based on genome expression data, we evaluated potential targets to restore sensitivity to MAPKi in partially reprogrammed cells. One of our candidates showed promising results by increasing apoptosis and differentiation after sequential treatment with BRAF and MEK inhibitors, in partially reprogrammed cells and human BRAFi-resistant cells. In summary, we show that partial reprogramming of melanoma cells is a feasible in vitro model to study resistance to MAPKi. Moreover, we suggest our candidate as a target to restore sensitivity of resistant cells to MAPKi which has significant clinical implications in the development of resistance to current treatments against melanoma.
Citation Format: Karol Granados, Laura Hüser, Aniello Federico, Sachindra Sachindra, Gretchen Wolff, Viktor Umansky, Jochen Utikal. Partial reprogramming of melanoma cells confers drug resistance and increased vulnerability to channel antagonists [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1274.
Collapse
Affiliation(s)
- Karol Granados
- 1German cancer research center (DKFZ), Heidelberg, Germany
| | - Laura Hüser
- 1German cancer research center (DKFZ), Heidelberg, Germany
| | | | | | | | - Viktor Umansky
- 1German cancer research center (DKFZ), Heidelberg, Germany
| | - Jochen Utikal
- 1German cancer research center (DKFZ), Heidelberg, Germany
| |
Collapse
|
33
|
Orouji E, Federico A, Larribère L, Novak D, Lipka DB, Assenov Y, Sachindra S, Hüser L, Granados K, Gebhardt C, Plass C, Umansky V, Utikal J. Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. Int J Cancer 2019; 145:3462-3477. [PMID: 31131878 DOI: 10.1002/ijc.32432] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Accepted: 05/06/2019] [Indexed: 12/29/2022]
Abstract
Alterations in histone modifications play a crucial role in the progression of various types of cancer. The histone methyltransferase SETDB1 catalyzes the addition of methyl groups to histone H3 at lysine 9. Here, we describe how overexpression of SETDB1 contributes to melanoma tumorigenesis. SETDB1 is highly amplified in melanoma cells and in the patient tumors. Increased expression of SETDB1, which correlates with SETDB1 amplification, is associated with a more aggressive phenotype in in vitro and in vivo studies. Mechanistically, SETDB1 implements its effects via regulation of thrombospondin 1, and the SET-domain of SETDB1 is essential for the maintenance of its tumorigenic activity. Inhibition of SETDB1 reduces cell growth in melanomas resistant to targeted treatments. Our results indicate that SETDB1 is a major driver of melanoma development and may serve as a potential future target for the treatment of this disease.
Collapse
Affiliation(s)
- Elias Orouji
- German Cancer Research Center (DKFZ), Skin Cancer Unit, Heidelberg, Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Baden Württemberg, Germany
| | - Aniello Federico
- German Cancer Research Center (DKFZ), Skin Cancer Unit, Heidelberg, Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Baden Württemberg, Germany
| | - Lionel Larribère
- German Cancer Research Center (DKFZ), Skin Cancer Unit, Heidelberg, Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Baden Württemberg, Germany
| | - Daniel Novak
- German Cancer Research Center (DKFZ), Skin Cancer Unit, Heidelberg, Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Baden Württemberg, Germany
| | - Daniel B Lipka
- Division of Epigenomics and Cancer Risk Factors, DKFZ, Heidelberg, Baden Württemberg, Germany
| | - Yassen Assenov
- Division of Epigenomics and Cancer Risk Factors, DKFZ, Heidelberg, Baden Württemberg, Germany
| | - Sachindra Sachindra
- German Cancer Research Center (DKFZ), Skin Cancer Unit, Heidelberg, Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Baden Württemberg, Germany
| | - Laura Hüser
- German Cancer Research Center (DKFZ), Skin Cancer Unit, Heidelberg, Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Baden Württemberg, Germany
| | - Karol Granados
- German Cancer Research Center (DKFZ), Skin Cancer Unit, Heidelberg, Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Baden Württemberg, Germany
| | - Christoffer Gebhardt
- German Cancer Research Center (DKFZ), Skin Cancer Unit, Heidelberg, Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Baden Württemberg, Germany.,Department of Dermatology and Venereology, University Hospital Hamburg-Eppendorf (UKE), Hamburg, Germany
| | - Christoph Plass
- Division of Epigenomics and Cancer Risk Factors, DKFZ, Heidelberg, Baden Württemberg, Germany
| | - Viktor Umansky
- German Cancer Research Center (DKFZ), Skin Cancer Unit, Heidelberg, Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Baden Württemberg, Germany
| | - Jochen Utikal
- German Cancer Research Center (DKFZ), Skin Cancer Unit, Heidelberg, Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Baden Württemberg, Germany
| |
Collapse
|
34
|
D'Alessandro V, Rentería F, Herrera J, Federico A, Barán E, Varas C, Diez G, Cano L, Andreozzi P, Antonioli C, Finocchiaro J, Ditondo J, Nabais I, Palmisciano V, Sirimarco L, Segal E. WS10-5 First report of cystic fibrosis patientś survival from a region of Argentina: data collected by its own Registry. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30176-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
35
|
Vinciguerra C, Giorgio A, Zhang J, Di Donato I, Stromillo ML, Tappa Brocci R, Federico A, Dotti MT, De Stefano N. Peak width of skeletonized mean diffusivity (PSMD) as marker of widespread white matter tissue damage in multiple sclerosis. Mult Scler Relat Disord 2018; 27:294-297. [PMID: 30448470 DOI: 10.1016/j.msard.2018.11.011] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Revised: 11/07/2018] [Accepted: 11/12/2018] [Indexed: 11/20/2022]
Abstract
BACKGROUND Peak width of skeletonized mean diffusivity (PSMD) is a novel and fully automated, MRI biomarker, which has shown clinical relevance in cerebral small vessel diseases (SVD). We aimed here to assess PSMD levels across the brain of patients with multiple sclerosis (MS), in comparison to normal controls (NC) and patients with CADASIL, a genetically defined form of severe SVD. METHODS We assessed PSMD in relapsing-remitting (RR) MS patients (n = 47) in comparison to age-matched CADASIL patients (n = 25) and NC (n = 28). Diffusion Tensor Imaging data were acquired on 1.5T MR clinical scanner to automatically compute PSMD through "skeletonization" of WM tracts and diffusion histograms. RESULTS RRMS had lower WM lesion volume (LV) than CADASIL (8.6 ± 8.2 vs 24.4 ± 17.4 cm3, p < 0.001). After correction for LV, PSMD values in MS were higher than in CADASIL patients (adjusted mean values: 4.5 vs 3.9 × 10-4 mm2/s, p = 0.03) and in both patient groups were higher than in NC (2.8 ± 0.3 × 10-4 mm2/s, p < 0.001). PSMD values correlated with LV in both patient groups (r = 0.8, p < 0.001 in MS; r = 0.6, p = 0.002 in CADASIL). CONCLUSIONS In both patient groups, PSMD was higher than in NC and closely correlated with LV, suggesting sensitivity in assessing brain tissue damage in these disorders. In MS patients, PSMD levels were higher than in CADASIL patients, despite the lower LV. This might be related to more severe normal-appearing WM abnormalities occurring in the MS brains. This novel, fully automated, MRI metric may represent a useful marker for a robust quantification of the diffuse WM tissue damage in MS.
Collapse
Affiliation(s)
- C Vinciguerra
- Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
| | - A Giorgio
- Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
| | - J Zhang
- Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
| | - I Di Donato
- Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
| | - M L Stromillo
- Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
| | - R Tappa Brocci
- Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
| | - A Federico
- Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
| | - M T Dotti
- Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
| | - N De Stefano
- Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
| |
Collapse
|
36
|
Gravina AG, Prevete N, Tuccillo C, De Musis C, Romano L, Federico A, de Paulis A, D’Argenio G, Romano M. Peptide Hp(2-20) accelerates healing of TNBS-induced colitis in the rat. United European Gastroenterol J 2018; 6:1428-1436. [PMID: 30386616 PMCID: PMC6206543 DOI: 10.1177/2050640618793564] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2018] [Accepted: 06/26/2018] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND AND AIMS Hp(2-20), a Helicobacter pylori-derived peptide interacting with N-formyl peptide receptors (FPRs), accelerates the healing of gastric injury in rats. Whether Hp(2-20) affects the recovery of inflamed colonic mucosa is unknown. We evaluated whether Hp(2-20) accelerated the healing of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis and explored the mechanism(s) underlying any such effect. METHODS Fifteen rats underwent rectal administration of Hp(2-20) 250-500 µg/kg/day, or of its control peptide Hp1 for 10 days, following induction of colitis with TNBS. Macroscopic and histological damage was quantified using predetermined injury scores. FPR1, COX-2, TNF-α, TGF-β, HB-EGF and tissue transglutaminase (t-TG) messenger RNA (mRNA) expression in colonic tissue was determined by quantitative polymerase chain reaction; FPR1, TNF-α and COX-2 protein levels by Western blotting. RESULTS (1) Hp(2-20) accelerated healing of TNBS-induced colitis compared to controls consistently with the expression of FPRs in colonic mucosa; (2) TNBS upregulated mRNA mucosal expression of COX-2, TNF-α, TGF-β, HB-EGF and t-TG and (3) this, with the exception of HB-EGF, was significantly counteracted by Hp(2-20). CONCLUSIONS Hp(2-20), an FPR agonist, accelerates the healing of TNBS-induced colitis in the rat. This effect is associated with a significant reduction in colonic tissue levels of COX-2, TGF-β, TNF-α and t-TG. We postulate that FPR-dependent pathways may be involved in the repair of inflamed colonic mucosa.
Collapse
Affiliation(s)
- AG Gravina
- Hepatogastroenterology Unit, Department
of Precision Medicine, University of Campania “Luigi Vanvitelli,” Naples,
Italy
| | - N Prevete
- Department of Translational Medical
Sciences (DiSMeT)-University of Naples Federico II and Institute of Endocrinology
and Experimental Oncology (IEOS) “G. Salvatore,” CNR, Naples, Italy
| | - C Tuccillo
- Hepatogastroenterology Unit, Department
of Precision Medicine, University of Campania “Luigi Vanvitelli,” Naples,
Italy
| | - C De Musis
- Hepatogastroenterology Unit, Department
of Precision Medicine, University of Campania “Luigi Vanvitelli,” Naples,
Italy
| | - L Romano
- Hepatogastroenterology Unit, Department
of Precision Medicine, University of Campania “Luigi Vanvitelli,” Naples,
Italy
| | - A Federico
- Hepatogastroenterology Unit, Department
of Precision Medicine, University of Campania “Luigi Vanvitelli,” Naples,
Italy
| | - A de Paulis
- Department of Translational Medical
Sciences (DiSMeT) and Center for Basic and Clinical Immunologic Research (CISI),
University of Naples Federico II, Naples, Italy
| | - G D’Argenio
- Gastroenterology Unit, Department of
Clinical and Experimental Medicine, University of Naples Federico II, Naples,
Italy
| | - M Romano
- Hepatogastroenterology Unit, Department
of Precision Medicine, University of Campania “Luigi Vanvitelli,” Naples,
Italy
| |
Collapse
|
37
|
Hüser L, Sachindra S, Granados K, Federico A, Larribère L, Novak D, Umansky V, Altevogt P, Utikal J. SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma. Int J Cancer 2018; 143:3131-3142. [PMID: 29905375 DOI: 10.1002/ijc.31609] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Revised: 04/06/2018] [Accepted: 05/03/2018] [Indexed: 12/19/2022]
Abstract
Melanoma is often characterized by a constitutively active RAS-RAF-MEK-ERK pathway. For targeted therapy, BRAF inhibitors are available that are powerful in the beginning but resistance occurs rather fast. A better understanding of the mechanisms of resistance is urgently needed to increase the success of the treatment. Here, we observed that SOX2 and CD24 are upregulated upon BRAF inhibitor treatment. A similar upregulation was seen in targeted therapy-resistant, melanoma-derived induced pluripotent cancer cells (iPCCs). SOX2 and CD24 are known to promote an undifferentiated and cancer stem cell-like phenotype associated with resistance. We, therefore, elucidated the role of SOX2 and CD24 in targeted therapy resistance in more detail. We found that the upregulation of SOX2 and CD24 required activation of STAT3 and that SOX2 induced the expression of CD24 by binding to its promoter. We find that the overexpression of SOX2 or CD24 significantly increases the resistance toward BRAF inhibitors, while SOX2 knock-down rendered cells more sensitivity toward treatment. The overexpression of CD24 or SOX2 induced Src and STAT3 activity. Importantly, by either CD24 knock-down or Src/STAT3 inhibition in resistant SOX2-overexpressing cells, the sensitivity toward BRAF inhibitors was re-established. Hence, we suggest a novel mechanism of adaptive resistance whereby BRAF inhibition is circumvented via the activation of STAT3, SOX2 and CD24. Thus, to prevent adaptive resistance, it might be beneficial to combine Src/STAT3 inhibitors together with MAPK pathway inhibitors.
Collapse
Affiliation(s)
- Laura Hüser
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, D-68135, Germany
| | - Sachindra Sachindra
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, D-68135, Germany
| | - Karol Granados
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, D-68135, Germany
| | - Aniello Federico
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, D-68135, Germany
| | - Lionel Larribère
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, D-68135, Germany
| | - Daniel Novak
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, D-68135, Germany
| | - Viktor Umansky
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, D-68135, Germany
| | - Peter Altevogt
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, D-68135, Germany
| | - Jochen Utikal
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, D-68135, Germany
| |
Collapse
|
38
|
Taglia I, Di Donato I, Bianchi S, Cerase A, Monti L, Marconi R, Orrico A, Rufa A, Federico A, Dotti MT. AARS2-related ovarioleukodystrophy: Clinical and neuroimaging features of three new cases. Acta Neurol Scand 2018; 138:278-283. [PMID: 29749055 DOI: 10.1111/ane.12954] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/18/2018] [Indexed: 02/03/2023]
Abstract
INTRODUCTION Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), previously known as hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS) or pigmentary orthochromatic leukodystrophy (POLD), is the most frequent non-vascular adult-onset leukoencephalopathy. It is caused by autosomal dominant mutations in CSF1R gene. Recently, also autosomal recessive mutations in AARS2 gene were found to be the cause of an adult-onset leukodystrophy with axonal spheroids. Our aim was to achieve a genetic diagnosis in a cohort of CSF1R-negative patients, performing a sequence analysis of AARS2 gene. MATERIAL AND METHODS AARS2 sequencing was performed in 38 CSF1R-negative patients with clinical and magnetic resonance imaging (MRI) findings of adult-onset leukoencephalopathy. RESULTS Three patients carrying AARS2 compound heterozygous mutations have been found. All patients were female with ovarian failure and leukoencephalopathy. In 2 patients, MRI findings were consistent with previous reports while the third patient showed focal white matter (WM) lesions in the centrum semiovale and the corpus callosum in the absence of extensive involvement and rarefaction of the WM. MRI spectroscopy showed the presence of increased lactate in 2 patients, thus linking AARS2-related leukoencephalopathy with other mitochondrial leukoencephalopathies with high levels of cerebral lactate. CONCLUSION We recommend screening for mutations in AARS2 gene in CSF1R-negative patients, also in the absence of a clear family history and peculiar MRI findings. Our results also suggest that findings of conventional MRI and MR spectroscopy may be useful in prompting the genetic screening.
Collapse
Affiliation(s)
- I. Taglia
- Department of Medicine, Surgery and Neurosciences; University of Siena; Siena Italy
| | - I. Di Donato
- Department of Medicine, Surgery and Neurosciences; University of Siena; Siena Italy
| | - S. Bianchi
- Department of Medicine, Surgery and Neurosciences; University of Siena; Siena Italy
| | - A. Cerase
- Unit of Neuroradiology; Department of Neurosciences; Azienda Ospedaliera Universitaria Senese; Siena Italy
| | - L. Monti
- Unit of Neuroradiology; Department of Neurosciences; Azienda Ospedaliera Universitaria Senese; Siena Italy
| | - R. Marconi
- Unit of Neurology; Misericordia Hospital; Grosseto Italy
| | - A. Orrico
- Molecular Medicine; Azienda Ospedaliera Universitaria Senese; Siena Italy
| | - A. Rufa
- Department of Medicine, Surgery and Neurosciences; University of Siena; Siena Italy
| | - A. Federico
- Department of Medicine, Surgery and Neurosciences; University of Siena; Siena Italy
| | - M. T. Dotti
- Department of Medicine, Surgery and Neurosciences; University of Siena; Siena Italy
| |
Collapse
|
39
|
Zaino D, Chiarotti I, Battisti C, Salvatore S, Federico A, Cerase A. Six-year clinical and MRI quantitative susceptibility mapping (QSM) follow-up in neurological Wilson's disease under zinc therapy: a case report. Neurol Sci 2018; 40:199-201. [PMID: 30209700 DOI: 10.1007/s10072-018-3557-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2018] [Accepted: 09/04/2018] [Indexed: 01/28/2023]
Affiliation(s)
- D Zaino
- Department of Medical, Surgical and Neurological Sciences, University of Siena, viale Mario Bracci n. 2, 53100, Siena, Italy.
| | - I Chiarotti
- Department of Medical, Surgical and Neurological Sciences, University of Siena, viale Mario Bracci n. 2, 53100, Siena, Italy
| | - C Battisti
- Department of Medical, Surgical and Neurological Sciences, University of Siena, viale Mario Bracci n. 2, 53100, Siena, Italy
| | - S Salvatore
- Department of Medical, Surgical and Neurological Sciences, University of Siena, viale Mario Bracci n. 2, 53100, Siena, Italy
| | - A Federico
- Department of Medical, Surgical and Neurological Sciences, University of Siena, viale Mario Bracci n. 2, 53100, Siena, Italy
| | - A Cerase
- Neuroimaging and Neurointervention Unit, Department of Neurological and Sensorineural Neurosciences, Azienda Ospedaliera Universitaria Senese, Policlinico "Santa Maria alle Scotte", Siena, Italy
| |
Collapse
|
40
|
Pati AR, Battisti C, Taglia I, Galluzzi P, Bianchi M, Federico A. A new case of autosomal dominant small vessel disease carrying a novel heterozygous mutation in HTRA1 gene: 2-year follow-up. Neurol Sci 2018; 39:1479-1481. [PMID: 29546604 DOI: 10.1007/s10072-018-3294-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Accepted: 02/15/2018] [Indexed: 10/17/2022]
Affiliation(s)
- A R Pati
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - C Battisti
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
| | - I Taglia
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - P Galluzzi
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - M Bianchi
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - A Federico
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| |
Collapse
|
41
|
Taglia I, Di Donato I, De Stefano N, Bianchi S, Galluzzi P, Federico A, Dotti MT. Blood–brain barrier permeability in a patient with Labrune syndrome due to
SNORD118
mutations. Eur J Neurol 2018; 25:e86-e87. [DOI: 10.1111/ene.13656] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Accepted: 03/22/2018] [Indexed: 02/02/2023]
Affiliation(s)
- I. Taglia
- Department of Medicine, Surgery and Neurosciences University of Siena Siena Italy
| | - I. Di Donato
- Department of Medicine, Surgery and Neurosciences University of Siena Siena Italy
| | - N. De Stefano
- Department of Medicine, Surgery and Neurosciences University of Siena Siena Italy
| | - S. Bianchi
- Department of Medicine, Surgery and Neurosciences University of Siena Siena Italy
| | - P. Galluzzi
- Unit of Diagnostic and Therapeutic Neuroradiology Azienda Ospedaliera Siena Siena Italy
| | - A. Federico
- Department of Medicine, Surgery and Neurosciences University of Siena Siena Italy
| | - M. T. Dotti
- Department of Medicine, Surgery and Neurosciences University of Siena Siena Italy
| |
Collapse
|
42
|
Cruccu G, Deuschl G, Federico A. Scientific publications of European neurologists: a survey commissioned by the European Academy of Neurology. Eur J Neurol 2018; 25:1128-1133. [PMID: 29687522 DOI: 10.1111/ene.13666] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Accepted: 02/26/2018] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND PURPOSE Bibliometric searches may provide an indirect assessment of research in a field or country. The European Academy of Neurology decided to investigate how article production was developing in European countries, as an indicator of neurological vitality. METHODS We searched two databases, Scopus and PubMed, for articles published by authors belonging to neurological institutions in all European countries, the USA, Brazil, China and Japan. The search assessed production in the period between 2000 and 2015. We calculated four indicators, i.e. gross neurological product (GNP) (which includes all articles published in any indexed journal), production in top neurological journals, GNP per inhabitant and GNP per gross domestic product. RESULTS All indicators greatly increased over time. The European GNP paralleled that of the USA and was higher than those of the other countries. Restricting the search to top neurological journals showed that, since 2012, European production grew faster than that of the USA. Germany had the highest production within Europe, Switzerland had the best ratio between GNP and inhabitants, and The Netherlands had the best ratio between GNP and gross domestic product. CONCLUSIONS Although this search had several limitations, the results were so straightforward that we can conclude that European neurology is highly active in the world. Future analyses should compare neurology with other main medical disciplines.
Collapse
Affiliation(s)
- G Cruccu
- Department of Neurology and Psychiatry, Sapienza University, Rome, Italy
| | - G Deuschl
- Department of Neurology, Universitätsklinikum Schleswig-Holstein, Christian-Albrechts University, Kiel, Germany
| | - A Federico
- Department of Medicine, Surgery and Neurosciences, Medical School, University of Siena and Chair of Scientific Committee, European Academy of Neurology, Siena, Italy
| |
Collapse
|
43
|
Dallio M, Masarone M, Errico S, Gravina AG, Nicolucci C, Di Sarno R, Gionti L, Tuccillo C, Persico M, Stiuso P, Diano N, Loguercio C, Federico A. Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study. Aliment Pharmacol Ther 2018; 47:826-837. [PMID: 29322544 DOI: 10.1111/apt.14499] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Revised: 06/24/2017] [Accepted: 12/10/2017] [Indexed: 02/07/2023]
Abstract
BACKGROUND Bisphenol A is an endocrine disrupting chemical associated with type 2 diabetes mellitus (T2DM), cardiovascular disease and liver enzyme abnormalities. AIM To evaluate bisphenol A plasma and urine levels in non-alcoholic fatty liver disease (NAFLD) patients compared to healthy subjects. Furthermore, we evaluated, in human HepG2 cells, the effects of exposure to different concentrations of bisphenol A on both oxidative stress induction and cell proliferation. METHODS We enrolled 60 patients with histological diagnosis of NAFLD with or without T2DM and sixty healthy subjects. In vitro, the proliferation of bisphenol A-exposed HepG2 cells at two different concentrations (0.025 and 0.05 μM) was evaluated, both at high (H-HepG2) and at low (L-HepG2) glucose concentrations for 48 h. Lipoperoxidation was assessed by thiobarbituric acid reactive substances (TBARS) assay. RESULTS Bisphenol A levels were significantly higher in 60 NAFLD subjects, both in urine and in plasma (P < 0.0001) when compared to controls and, in this group, it appeared to be higher in 30 non-alcoholic steatohepatitis patients compared to 30 simple steatosis subjects (P < 0.05), independently from the presence of T2DM. After a bisphenol A-free diet for 1 month, NAFLD patients showed a significant reduction in bisphenol A circulating levels (P < 0.05), without a significant reduction in urine levels. H-HepG2 cells treated with bisphenol A (0.05 μM) increased proliferation compared to controls at 48 h (P < 0.0001). Bisphenol A increased TBARS levels at 48 h versus controls. CONCLUSIONS Our study reveals a possible role of bisphenol A as an environmental factor involved in the promotion of NAFLD, particularly in T2DM patients.
Collapse
Affiliation(s)
- M Dallio
- Department of Clinical and Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - M Masarone
- Department of Medicine and Surgery, University of Salerno, Baronissi, Salerno, Italy
| | - S Errico
- Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - A G Gravina
- Department of Clinical and Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - C Nicolucci
- Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - R Di Sarno
- Department of Clinical and Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - L Gionti
- Department of Clinical and Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - C Tuccillo
- Department of Clinical and Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - M Persico
- Department of Medicine and Surgery, University of Salerno, Baronissi, Salerno, Italy
| | - P Stiuso
- Department of Biochemistry, Biophysics and General Pathology, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - N Diano
- Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - C Loguercio
- Department of Clinical and Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - A Federico
- Department of Clinical and Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| |
Collapse
|
44
|
Abstract
Abstract
Histone modifications play a significant role in the development and progression of various cancers. The histone methyltransferase SETDB1 (SET domain, bifurcated 1) catalyzes the addition of methyl groups to histone H3 at lysine 9 (H3K9). In the present study, we demonstrate that SETDB1 contributes to melanoma tumorigenesis. We show SETDB1 to be highly amplified in melanoma tissues of patients with poor prognosis. The amplification of SETDB1 correlates with the increased expression of the protein.
Functional studies show an increased SETDB1 expression to be associated with a more proliferative, invasive and migratory phenotype and give rise to larger tumor masses in xenograft mouse models. In human primary melanomas, SETDB1 expression is elevated at the invasive borders. The activity of SETDB1 can be blocked by small molecules, which leads to reduced cell growth even in melanoma cell lines that are resistant towards BRAF and MEK inhibitors.
In conclusion, our findings support SETDB1 as a major driver of melanoma development and progression. We therefore suggest SETB1 as a potential future target for the treatment of melanoma.
Citation Format: Elias Orouji, Aniello Federico, Lionel Larribere, Daniel Novak, Jochen Utikal. The histone methyltransferase SETDB1 contributes to melanoma tumorigenesis [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A180.
Collapse
Affiliation(s)
| | | | | | - Daniel Novak
- 2German Cancer Research Center, Heidelberg, Germany
| | | |
Collapse
|
45
|
Donnini I, Rinnoci V, Nannucci S, Valenti R, Pescini F, Mariani G, Bianchi S, Dotti MT, Federico A, Inzitari D, Pantoni L. Pregnancy in CADASIL. Acta Neurol Scand 2017; 136:668-671. [PMID: 28608406 DOI: 10.1111/ane.12784] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/15/2017] [Indexed: 11/30/2022]
Abstract
OBJECTIVES Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited cerebral small vessel disease caused by NOTCH3 gene mutations. CADASIL women are frequently considered at high risk of systemic vascular events during pregnancy and often prescribed with antithrombotic drugs. This decision is not evidence-based considering the lack of data about pregnancy outcome in CADASIL. We describe our experience on pregnancy in CADASIL patients. MATERIALS AND METHODS We reviewed records of 50 CADASIL females followed in our center, and we collected prospective information in six patients for a total of 93 pregnancies. RESULTS No woman had the disease onset or suffered from cerebral vascular ischemic events during pregnancy. Sixteen miscarriages (17.2%) were recorded. There were 72 vaginal births, and five cesarean sections. Considering the six patients followed prospectively (for a total of eight pregnancies), data on fetal growth and newborns weight were in line with those from the general population. Considering gestational complications, we recorded mild proteinuria without hypertension in one patient and hyperinsulinemia and pre-eclampsia in another affected by a known nephropathy. Antithrombotic drugs were used in three patients, in one for an unrelated coexisting prothrombotic condition. CONCLUSIONS CADASIL does not seem to be associated with an unfavorable outcome of pregnancy either for women and fetuses. Patients and treating physicians should be reassured that pregnancy can be safely initiated in CADASIL, as there is no evidence to support a specific preventive antithrombotic treatment during pregnancy in CADASIL. Larger studies are needed to definitively confirm these conclusions.
Collapse
Affiliation(s)
- I. Donnini
- NEUROFARBA Department; University of Florence; Florence Italy
| | - V. Rinnoci
- NEUROFARBA Department; University of Florence; Florence Italy
| | - S. Nannucci
- NEUROFARBA Department; University of Florence; Florence Italy
- Department of Emergency Neurology; C. Mondino National Neurological Institute; Pavia Italy
| | - R. Valenti
- NEUROFARBA Department; University of Florence; Florence Italy
| | - F. Pescini
- Stroke Unit; Emergency Department; Azienda Ospedaliero Universitaria Careggi; Florence Italy
| | - G. Mariani
- Gynecology and Obstetrics Department; University of Florence; Florence Italy
| | - S. Bianchi
- Department of Medical Surgical and Neurological Sciences; University of Siena; Siena Italy
| | - M. T. Dotti
- Department of Medical Surgical and Neurological Sciences; University of Siena; Siena Italy
| | - A. Federico
- Department of Medical Surgical and Neurological Sciences; University of Siena; Siena Italy
| | - D. Inzitari
- NEUROFARBA Department; University of Florence; Florence Italy
| | - L. Pantoni
- NEUROFARBA Department; University of Florence; Florence Italy
| |
Collapse
|
46
|
Pretegiani E, Rosini F, Rufa A, Gallus G, Cardaioli E, Da Pozzo P, Bianchi S, Serchi V, Collura M, Franceschini R, Bianchi Marzoli S, Dotti M, Federico A. Genotype-phenotype and OCT correlations in Autosomal Dominant Optic Atrophy related to OPA1 gene mutations: Report of 13 Italian families. J Neurol Sci 2017; 382:29-35. [DOI: 10.1016/j.jns.2017.09.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2017] [Revised: 09/09/2017] [Accepted: 09/12/2017] [Indexed: 10/18/2022]
|
47
|
Federico A. Neurology and migrants: What we know, what we learned by neurosciences, what we can do? J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
48
|
Pati AR, Battisti C, Tripodi SA, Cerase A, Vella A, Guidi L, Mignarri A, Dotti MT, Federico A. Neuroendocrine lung cancer in a patient with limbic encephalopathy due to anti-Hu antibodies: A rare association not to be missed. J Neurol Sci 2017; 378:91-93. [PMID: 28566188 DOI: 10.1016/j.jns.2017.04.032] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 04/13/2017] [Accepted: 04/19/2017] [Indexed: 10/19/2022]
Affiliation(s)
- A R Pati
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - C Battisti
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | | | - A Cerase
- Unit of Neuroradiology, Department of Neurosciences, AOUS, Siena, Italy
| | - A Vella
- Nuclear Medicine, AOUS, Siena, Italy
| | - L Guidi
- Unit of Neurology, Hospital of Empoli, Italy
| | - A Mignarri
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - M T Dotti
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
| | - A Federico
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| |
Collapse
|
49
|
Iadevaia MD, Sgambato D, Miranda A, Ferrante E, Federico A, Sasso FC, D'Armiento FP, Palla M, Romano M. Amelanotic metastatic melanoma of the stomach presenting with iron deficiency anemia. Acta Gastroenterol Belg 2017; 80:327-328. [PMID: 29560705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Affiliation(s)
- M D Iadevaia
- Department of Internal and Experimental Medicine "Magrassi-Lanzara", Second University of Naples, Via Pansini, 80131, Naples (Italy)
| | - D Sgambato
- Department of Internal and Experimental Medicine "Magrassi-Lanzara", Second University of Naples, Via Pansini, 80131, Naples (Italy)
| | - A Miranda
- Department of Internal and Experimental Medicine "Magrassi-Lanzara", Second University of Naples, Via Pansini, 80131, Naples (Italy)
| | - E Ferrante
- Department of Internal and Experimental Medicine "Magrassi-Lanzara", Second University of Naples, Via Pansini, 80131, Naples (Italy)
| | - A Federico
- Department of Internal and Experimental Medicine "Magrassi-Lanzara", Second University of Naples, Via Pansini, 80131, Naples (Italy)
| | - F C Sasso
- Department of Internal and Experimental Medicine "Magrassi-Lanzara", Second University of Naples, Via Pansini, 80131, Naples (Italy)
| | - F P D'Armiento
- Department of Advanced Biomedical Sciences, Section of Pathology, Federico II University, Via Pansini 5, 80131 Naples (Italy)
| | - M Palla
- O.U. Melanoma, Cancer Immunotherapy and Innovative Therapies, National Cancer Institute of Naples "G. Pascale" Foundation, Naples, Italy
| | - M Romano
- Department of Internal and Experimental Medicine "Magrassi-Lanzara", Second University of Naples, Via Pansini, 80131, Naples (Italy)
| |
Collapse
|
50
|
Pati AR, Capecchi PL, Malandrini A, Federico A, Mignarri A. Polyneuropathy with demyelinating changes in Churg-Strauss syndrome: an unusual association. Neurol Sci 2016; 38:695-697. [PMID: 28025723 DOI: 10.1007/s10072-016-2789-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Accepted: 11/30/2016] [Indexed: 11/25/2022]
Affiliation(s)
- A R Pati
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - P L Capecchi
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - A Malandrini
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - A Federico
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - A Mignarri
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
| |
Collapse
|